PF-07304814
Protocol C4611001Final Protocol Amendment 4, 15 December 2020
PFIZER CONFIDENTIAL
Page 1
A PHASE 1B, 2-PART, DOUBLE-BLIND, PLACEBO-CONTROLLED, 
SPONSOR-OPEN STUDY, TO EVALUATE THE SAFETY, TOLERABILITY AND 
PHARMACOKINETICS OF SINGLE ASCENDING (24-HOUR, PART 1) AND
MULTIPLE ASCENDING (120-HOUR, PART 2) INTRAVENOUS INFUSIONS OF 
PF-07304814 IN HOSPITALIZED PARTICIPANTS WITH COVID-19
Study Intervention Number: PF-07304814
Study Intervention Name: N/A
US IND Number:
EudraCT Number: 2020-003905-73
Protocol Number: C4611001
Phase: Phase 1b
Short Title: A Phase 1b First-In-Human Study to Evaluate Safety, Tolerability, And 
Pharmacokinetics Following Single Ascending And Multiple Ascending Doses, of PF-07304814 In Hospitalized Participants With COVID-19
This document and accompanying materials contain confidential information belonging to Pfizer. Except as 
otherwise agreed to in writing, by accepting or reviewing these documents, you agree to hold this information in confidence and not copy or disclose it to others (except where required by applicable law) or use it for unauthorized purposes. In the event of any actual or suspected breach of this obligation, Pfizer must be 
promptly notified.CCI
PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 202 0
PFIZER CONFIDENTIAL
Page 2Protocol Amendment Summary of Changes Table
Document History
Document Version Date Summary and Rationale for Changes
Amendment 
415December 
2020This amendment is undertaken following acquisition of 
14-daytoxicology  data and discussions with regulatory  
authorit ieswhich allowed for the stud y design to include 
the possibility  of escalating the dose in Part 2. All 
sections of the protocol were impa cted.The substantial 
changes are presented below:
1.Updated s tudy design to replace Part 2 designation 
from “Extended Infusion” 
to“Multiple Ascending 
Dose (MAD)” (all sections) .
2.Updated stud y design to add 1 additional planned 
cohort and 1 additional opti onal cohort in Part 2 
making a total of 2 planned and 2 optio nal cohorts in 
Part2. (Section 1 and Section 4) .
3.
Updated planned number of participants from 56 to 
72 to account for 2 additional cohorts being added in 
Part2 (Section 1 and Section 4) .
4.Added startingdose in first cohort in Part 2, 
Cohort 6 (Section 
1 and Section 4 ).
5.Updated non- clinical and clinical overview 
summaries (Section 2).
6.Updated benefit/ risk assessment (Section 2).
7.Addedstatement that an y dose escalation decision in 
Part2 will oc cur onl yafter discussion with
competent regulatory  authorities, thereb y removing 
the need for IRC in Part 2.
8.Updated dose escalation and stopping rules to 
address both Part 1 and Part 2 (Section 6) .
Other substantial changes: 
1.Added additional study  inter vention formulation 
(powder form) to be used for participants enrolled in 

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 202 0
PFIZER CONFIDENTIAL
Page 4required PK blood draw at 12 hr and 32 hr in 
Part 1: SAD (24 -h infusion).
ii.Removed PK blood draws at 12 hr and 1 32hr in 
Part 2: Extended I nfusion (120-h infusion).
iii.Updated total blood sampling volume to account 
for reduced PK blood draws.
Rationale : The frequency of blood draws reduced as 
per request by  the FD A.
Sections Impacted: 
Section 1.3: SoA Table Part 2: Extended Infusion
Section 10.2: Clinic al Laboratory Tests
Change : Added coagulation panel as additional 
assessme nt.
Rationale : The assessment frequency  of coagulation 
markers was increased to align wit h other safet y labs 
in Part 2. 
Sections Impacted: 
Section 1.2: Schema
Section 2.3: Benefit/ Risk Assessment
Section 4
.1: Overall Design
Section 4.3: Justification for Dose
Changes: 
i.Changed number of planned Cohorts in Part 1 
from 3 to 2 and number of optional cohorts from 2 to 
3 –in Schema.
ii. Updated highest planned dose in Part 1 from 
5000 mg to 1000 mg.
iii. Removed the values/estimations of doses for 
Cohort
3 in Part 1 and Cohort 6 and 7 in Part 2. 
Rationale : Due to the revised PK stopping limit s and 
to align with feedback received from the FDA, doses 
higher than 1000 mg will be determined after review 
of the safet y and PK data of previous cohorts. For 
Part 1 , these newl y identified doses may  be evaluated 

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 202 0
PFIZER CONFIDENTIAL
Page 5in optional cohorts (Cohort 3-5) in Part 1.Dose s in
Part 2 (Cohort 6 and Cohort 7) will be de termined
after careful review of available data from Part 1, as 
well as emerging data from study  C4611007 and 
agreement with the competent regulatory  authority. 
Sections Impacted: 
Section 2.2.1.3: Non -clinical Safety
Section 2.2.2: Clinical Overview
Section 4.3
:Justification for Dose
Section 6.6: Dose Modification
Change : PK stopping limits revised to align with 
exposures from the 70 mg/kg 14 -day continuous 
infusion in non
-human primates.
Rationale : The purpose to lower the PK stopping 
limits of the study  is to limit participant risk and is in 
alignment with feedback received from the FDA.
Sections Impacted: 
Section 2.3: Benefit/Risk Assessment
Section 5.2: Exclusion Crit eria
Changes:
i.Added the addi tional risk ofthrombotic event, 
DVT or PE, due to study  intervention.
ii.Added exclusion criterion forparticipants with 
history  of venous thromboembolic event, 
including deep venous thrombosis or pulmonary  
embolism.
Rationale : Changes made to reduce ove rall 
participant risk as the study  population is at higher 
risk of developing thrombotic complications as a 
result of 
disease progression .
Sections Impacted: 
Section 5.2: Exclusion Criteria
Section 
6.5: Concomitant Therapy
Section 10.4 Female Participant R eproductive 
Inclusion Criteria
Change : Added criteri ato exclude women using 

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 202 0
PFIZER CONFIDENTIAL
Page 6hormonal therap y as contraception method or as 
replacement therap y to manage post -menopa usal 
symptoms.
Rationale : Hormones used for female contraception 
or as replacement therap ies may  increase the risk of 
developing thrombotic even ts.
Sections Impacted: 
Section 3: Objectives, Estimands, and Endpoints
Section 9.4.2. Secondary Endpoint: 
Phar macokinetic Analyses
Change: Plasma PK parameters from Part 1 
updated. Onl y C24 and C24 ( dn) will be reported. 
Rationale: Due to reduced PK sampling in Part 1, 
some PK parameters cannot be accuratel y estimated, 
therefore, not reported. 
This amendment is making the following 
nonsub
stantial changes:
Sections Impacted
Section 1.3: Schedule of Activities (Part 1 and
Part 2)
Section 8.2.3: Electrocardiograms
Change : Added additional time window for ECG 
assessments.
Sections Impacted:
Section 1.2: Schema
Secti on4.1.1: Overall Design Part 1: SAD
Change: Changed 1.0- fold to 1 -fold
Section 2.2.2: C linical Overview
Change : Changed the sentence from “The stud y is 
planned to begin in Oct -2020 ” to “The stud y began 
inOct-2020” to align with the Amendment date.
Amen dment 16 October This amendment is making the following substantial 

PF-07304814
Protocol C4611001Final Protocol Amendment 4, 15 December 2020
PFIZER CONFIDENTIAL
Page 72 2020 changes:
•Sections Impacted: 
Section 1.3: SoA Table Section 8: Study Assessments and Procedures Change: 
i. Removed PK blood draws at 0.5 hr, 26 hr, and 
30 hr and made 2 hr PK blood draw optional in Part 1: SAD (24-h infusion).
ii. Made 6 hr blood draws for selected biomarkers 
(including plasma PD biomarker, serum PD biomarker, and banked biospecimen [Prep D1]) optional in Part 1: SAD (24-h infusion).
iii. Removed biomarker blood collection for 
specified viral genetics in Part 1: SAD (24-h infusion) and Part 2: Extended Infusion (120-h infusion).
iv.Removed 12-lead triplicate ECG assessments at 0.5 
hr and 2 hr timepoints in Part 1: SAD (24-hr infusion).
Rationale : The frequency of blood draws reduced 
or made optional to lessen burden on the patient. Similarly, frequency of collection of ECG reduced on Day 1 to lower the burden on the site coordinator/nurse and to limit the contact with the patient.  
•Sections Impacted : 
Protocol Title Section 1: Protocol Summary (Synopsis)Section 2: IntroductionSection 4: Study DesignSection 5: Study Population
Change : Broadened the inclusion range of patient 
severity by allowing patients with severe symptoms of COVID-19, with some limitations.
•Removed exclusion criterion #1d.
 
CCI
PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 202 0
PFIZER CONFIDENTIAL
Page 14transporters. 
Rationale : PF-00835231 has the potential to be a 
time-dependent inhibitor of CYP3A and in hibitor of 
P
-gp, BCRP, OATP1B1/1B3, OCT1, and 
MATE1/2K transporters at higher doses. Therefore, 
additional text was included to highlight this 
possible risk. 
This Ame ndment is making the following 
non-substantial changes:
Section : 5.2; Exclusion Criterion #12.
Change: Clarification that investigational 
drugs/treatments used as for COVID -19 treatment 
are allowed, when these are given as part of an 
open -
label stud y.
Section 8.5 ; Pharmacokinetic s.
Change : K2EDTA changed to K 3EDTA to correct a 
typographical er ror.
Section 9.6; Data Monitoring Committee or Other 
Independent Oversight Committee .
Change : deleted “internal” from independent I RC as 
it was a ty pographical error . 
Section 10.2; Appendix 2: Clinical L aboratory  tests .
Change : Removed fasting requireme nt from glucose 
(in Table 10).
Change : Added phosphorus to clinical chemistry  
tests, as requested b y the FDA.
Section 10.4
.4; Appendix 4: Contraception 
Methods.
Change : Replaced bullets to a numbered list of 
contraception methods.
Original 
protocol04 Aug ust 2020 N/A

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 202 0
PFIZER CONFIDENTIAL
Page 15This amendment incorporates all revisions to date, including amendments made at the 
request of country  health authorities and IRBs/ECs.

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 202 0
PFIZER CONFIDENTIAL
Page 16TABLE OF CONTEN TS
LIST OF TABLES ................................ ................................ ................................ ................... 21
1.PROTOCOL  SUMMARY ...................................................................................................22
1.1. Sy nopsis ..................................................................................................................22
1.2. Schema ....................................................................................................................26
1.3. Schedule of Activities .............................................................................................29
2. INTRODUCTION ...............................................................................................................36
2.1.Study  Rationale .......................................................................................................36
2.2. Background .............................................................................................................36
2.2.1. Non
-clinical Overview ................................................................................38
2.2.1.1. Non
-clinical Pharma cology :......................................................38
2.2.1.2. Nonclinical Pharmacokinetics and Metabolism ........................44
2.2.1.3. Non
-clinical Safety ....................................................................45
2.2.2. Clinical Overview ................................ ................................ ....................... 46
2.2.2.1. Study  C4611007 - Ongoing.......................................................47
2.3. Benefit/Risk Assessment
.........................................................................................48
2.3.1. Risk Assessment
.........................................................................................49
2.3.2. Benefit Assessment .....................................................................................51
2.3.3. Overall Benefit/Risk Conclusion ................................................................51
3.OBJECTI VES, ESTIMAN DS, AND ENDPOINTS ...........................................................51
4. STUDY DESIGN .................................................................................................................53
4.1.Overall Design .........................................................................................................53
4.1.1. Part 1: SAD .................................................................................................53
4.1.2. Part 2: MAD
...............................................................................................54
4.2.
Scientific Rationale for Study  Design ................................ ................................ .....54
4.3. Justification for Dose ..............................................................................................55
4.3.1. Rationale for Dose Selection ................................ ................................ ......55
4.3.2. Starting Dose a nd Dose Escalation in Part 1: SAD ................................ ....55
4.3.3. Starting Dose and Dose Selection in Part 2: MAD.....................................56
4.4. End of Study  Definition ..........................................................................................57
5. STUDY POPUL ATION
................................ ................................ ................................ ......58

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 202 0
PFIZER CONFIDENTIAL
Page 175.1.Inclusion Criteria.....................................................................................................58
5.2.Exclusion Criteria ....................................................................................................59
5.3.Lifesty le Considerations ..........................................................................................62
5.3.1. Contraception ..............................................................................................62
5.4. Screen Failures ........................................................................................................62
5.5. Criteria for Temporarily  Delay ing Enrolment/Randomization/Study  
Intervention Administration ......................................................................................62
6. STUDY INTERVENTIO N
..................................................................................................62
6.1. Study  Intervention(s) Administered ........................................................................62
6.1.1. Administration ............................................................................................62
6.2.
Preparation/Handling/Storage/Ac countability ........................................................64
6.2.1. Preparation and Dispensing ........................................................................65
6.3. Measures to Minimize Bias: Randomization and Blinding .....................................65
6.3.1. Allocation to Study Intervention ................................................................65
6.3.2. Breaking th
e Blind ......................................................................................66
6.4.Study  Intervention Compliance ...............................................................................66
6.5. Concomitant Therapy ..............................................................................................67
6.5.1. Rescue Medicine .........................................................................................67
6.6. Dose Modification ...................................................................................................67
6.6.1. Dose Escalation and Stoppin
g Rules ..........................................................67
6.7. I ntervention After the End of the Study ..................................................................70
7. DI SCONTINUATION O F STUDY INTERVENTION AND PARTI CIPANT 
DISCONTINUATION/WI THDRAWAL ...........................................................................70
7.1.Discontinuation of Study  Intervention ....................................................................70
7.1.1. Tempora ry Discontinuation ................................ ................................ ........ 71
7.1.2. Rechalle nge.................................................................................................71
7.2. Participant Discontinuation/Withdrawal From the Study ................................ .......71
7.2.1. Withdrawal of Consent ................................ ................................ ............... 72
7.3. L ost to Follow -up ....................................................................................................72
8.
STUDY ASSESSMENTS AND PROCEDURES................................ ............................... 73
8.1. Efficacy  Assessments ..............................................................................................74
8.2.Safet y Assessments .................................................................................................74

PF-07304814
Protocol C4611001Final Protocol Amendment 4, 15 December 2020
PFIZER CONFIDENTIAL
Page 188.2.1. Physical Examinations................................................................................74
8.2.2. Vital Signs ..................................................................................................748.2.3. Electrocardiograms.....................................................................................75
8.2.3.1. Continuous Cardiac Monitoring by Telemetry .........................75
8.2.4. Clinical Safety La boratory Asse ssments ....................................................76
8.2.5. Pregnancy Testing ......................................................................................76
8.3. Adverse Events and Serious Adverse Events..........................................................77
8.3.1. Time Period and Frequency for Collecting AE and SAE Information.......77
8.3.1.1. Reporting SAEs to Pfizer Safety...............................................788.3.1.2. Recording Nonserious AEs and SAEs on the CRF...................78
8.3.2. Method of Detecting AEs and SAEs ..........................................................788.3.3. Follow-up of AEs and SAEs.......................................................................788.3.4. Regulatory Reporting Requirements for SAEs...........................................788.3.5. Exposure During Pregnancy or Breastfeeding, and Occupational 
Exposure ..........................................................................................................79
8.3.5.1. Exposure During Pregnancy......................................................798.3.5.2. Exposure During Breastfeeding ................................................818.3.5.3. Occupational Exposure .............................................................81
8.3.6. Cardiovascular and Death Events...............................................................818.3.7. Disease Related Events and/or Disease Related Outcomes Not 
Qualifying as AEs or SAEs..............................................................................81
8.3.8. Adverse Events of Special Interest.............................................................82
8.3.8.1. Lack of Efficacy........................................................................82
8.3.9. Medical Device Deficiencies......................................................................828.3.10. Medication Errors .....................................................................................82
8.4. Treatment of Overdose............................................................................................828.5. Pharmacokinetics ....................................................................................................83
8.5.1. Plasma for Analysis of PF-07304814 and PF-00835231 ...........................83
8.5.3. Urine for Analysis of PK PF-00835231  
...........................................................................................................84
CCI
CCI
CCI
PF-07304814
Protocol C4611001Final Protocol Amendment 4, 15 December 2020
PFIZER CONFIDENTIAL
Page 198.8. Biomarkers ..............................................................................................................86
8.8.2. Specified Viral Genetics (RNA).................................................................87
8.8.3. Viral Load Assessment...............................................................................87
8.8.5. Specified Protein Research .........................................................................88
8.8.5.1. Plasma PD Biomarker Assessments..........................................888.8.5.2. Serum PD Biomarker Assessments...........................................88
8.9. Immunogenicity Assessments .................................................................................88
8.10. Health Economics .................................................................................................88
9. STATISTICAL C ONSIDERATIONS ................................................................................88
9.1. Estimands and Statistical Hypotheses .....................................................................899.2. Sample Size Determination.....................................................................................899.3. Analysis Sets ...........................................................................................................899.4. Statistical Analyses .................................................................................................90
9.4.1. Primary Endpoi nt: Safety ...........................................................................90
9.4.1.1. Electrocardiogram Analyses......................................................90
9.4.2. Secondary Endpoint: Pharmacokinetic Analyses .......................................91
9.4.2.1. Derivation of Pharmacokinetic Parameters...............................919.4.2.2. Statistical Methods for PK Data................................................92
9.4.3. Tertiary/Explorat ory Endpoints ..................................................................92
9.5. Interim Analyses .....................................................................................................92
9.6. Data Monitoring Committee or Other Independent Oversight Committee.............93
10. SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS ..........................................................................................................94
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ...............94
10.1.1. Regulatory and Ethical Considerations ....................................................94CCI
CCI
CCI
CCI
CCI
PF-07304814
Protocol C4611001Final Protocol Amendment 4, 15 December 2020
PFIZER CONFIDENTIAL
Page 2010.1.1.1. Reporting of Safety Issues and Serious Breaches of the 
Protocol or ICH GCP.........................................................................94
10.1.2. Financial Disclosure .................................................................................9510.1.3. Informed Consent Process ........................................................................9510.1.4. Data Protection .........................................................................................9610.1.5. Dissemination of Clinical Study Data ......................................................9610.1.6. Data Qualit y Assurance ............................................................................98
10.1.7. Source Documents....................................................................................9910.1.8. Study and Site Start and Closure ..............................................................9910.1.9. Publication Policy...................................................................................10010.1.10. Sponsor’s Qualified Medical Personnel ...............................................101
10.2. Appendix 2: Clinical Laboratory Tests ...............................................................10210.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow-up, and Reporting ....................................................................103
10.3.1. Definition of AE .....................................................................................10310.3.2. Definition of SAE...................................................................................10410.3.3. Recording/Reporting and Follow-up of AEs and/or SAEs.....................10610.3.4. Reporting of SAEs..................................................................................109
10.4. Appendix 4: Contraceptive Guidance .................................................................110
10.4.1. Male Participant Reproductive Inclusion Criteria ..................................11010.4.2. Female Participant Reproductive Inclusion Criteria...............................11010.4.3. Woman of Childbearing Potential ..........................................................11110.4.4. Contraception Methods...........................................................................112
10.6. Appendix 6: Liver Safety: Suggested Actions and Follow-up Assessments ......114
10.7. Appendix 7: ECG Findings of Potential Clinical Concern .................................11610.8. Appendix 8: Prohibited Medications...................................................................11810.9. Appendix 9: Abbreviations .................................................................................119
11. REFERENCES ................................................................................................................1 24
CCI
PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 202 0
PFIZER CONFIDENTIAL
Page 21LIST OF TABLES
Table 1. Assay  Conditions to Assess the An tiviral SARS -CoV -1 and 
SARS -CoV -2 Activity  of PF -07304814 and PF- 00835231 .....................38
Table 2. Summary  of PF
-00835231 and Remdesivir Inhibition of SARS -
CoV -2 Expression in A549 -ACE2 Cells ..................................................39
Table 3. PF-00835231 and Remdesivir inhibition of SARS CoV2 expression 
in HeLa -ACE2 cells ..................................................................................39
Table 4. Summary  of the In Vitro Antiviral Activity , Cytotoxicity , and TI 
for PF -00835231 With and Without the P -gp Efflux I nhibitor, 
CP-
100356 ................................................................................................41
Table 5. Predicted Human Plasma Total Exposure and Safety  Margins of 
PF-00835231 Relative to Expos
ure L imits at Planned Dose Levels ........57
Table 6. Predicted Human Exposure and Safet y Margins of PF -
07304814 
Relative to Exposure L imits at Planned Dose Levels ...............................57
Table 7. Plasma PF -07304814 and PF -
00835231 PK Parameters Definitions 
for Part 1: SAD (24- h Continuous I nfusion) ............................................91
Table 8. Plasma PF -07304814 and PF -00835231 PK Para meters for Part 2: 
MAD (120 -h Continuous I nfusion) ................................ .......................... 91
Table 9. Urine PF -00835231 PK Parameters Definitions for Part 1: SAD 
(24-h Continuous I nfusion) .......................................................................92
Table 10. Protocol -Required Safet y Laboratory  Assessments ...............................102
Table 11. Common Medications That I nhibit CYP450 3A4a.................................118
Table12. Common Medications That I nduce CYP450 3A4a.................................118

PF-07304814
Protocol C4611001Final Protocol Amendment 4, 15 December 2020
PFIZER CONFIDENTIAL
Page 221. PROTOCOL SUMMARY
1.1. SynopsisShort Title: A Phase 1b First-In-Human Study to Evaluate Safety, Tolerability, And 
Pharmacokinetics Following Single Ascending And Multiple Ascending Doses, of PF-07304814 In Hospitalized Participants With COVID-19. 
Rationale: The current study is the first clinical administration with PF-07304814 (prodrug), 
and its active moiety, PF-00835231, is a potent and selective inhibitor of the SARS-CoV-2 3CL protease. It is designed as a 2-part study in hospitalized COVID-19 patients as a randomized, double-blind, sponsor-open, parallel group, placebo-controlled trial. Part 1 is to evaluate safety, tolerability, PK and markers of clinical activity of escalating doses of PF-07304814 given as 24-hour IV infusions. Part 2 is to evaluate safety, tolerability, PK and markers of clinical activity of escalating dose s of PF-07304814 given as 120-hour IV 
infusions.
Objectives, Estimands, And Endpoints
Objectives Estimands Endpoints
Primary: Primary: Primary: 
•To assess the safety and 
tolerability following single 
and multiple ascending doses 
of PF-07304814 in hospitalized participants with COVID-19.N/A •Frequency, severity, and causal 
relationship of TEAEs and withdrawals 
due to TEAEs (including infusion site 
reactions).
•Frequency and magnitude of abnormal 
laboratory findings.
•Changes from baseline in vital sign 
measurements, pulse oximetry/SpO 2, and
12-lead ECG parameters.
Secondary: Secondary: Secondary: 
•To evaluate the plasma PK of 
PF-07304814 and PF-00835231 and urinary PK 
of PF-00835231 following 
single and multiple ascending doses in hospitalized participants with COVID-19.N/A Part 1: SAD
•PF-07304814 (prodrug) and PF-00835231 
(active moiety) plasma PK:C
24 (end of infusion) and C 24 (dn).
•PF-00835231 urinary PK parameters: Ae, 
Ae%.
Part 2: MAD
•PF-07304814 (prodrug) and PF-00835231 
(active moiety) plasma PK:
C120 (end of infusion), C max, Css, and t ½.
Tertiary/Exploratory: Tertiary/Exploratory: Tertiary/Exploratory: 
  C
CI
PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 202 0
PFIZER CONFIDENTIAL
Page 24Overall Design:
This is a First -In-Human Phase 1b study  to evaluate the safety , tolerability  and PK of 
PF-07304814 in participants who a re hospitalized for treatment of COVID -19.The 
participants will be receiv ing SoC therap y for the treatment of mild, moderate, or severe 
COVID -19, but will not be eligible if they  require mechanical ventilation or ECMO at 
screening or baseline. All partici pants will have a confirmed positive test for SARS -CoV - 2 
(see Section 5.1 for details) and onset of s ymptoms within 15 days of Screening .For 
inclusion into Part 2 : MAD of the stud y, participants will be required to have had a positive 
test for SARS- CoV -2 (see Section 5.1 for details) within 72 hours prior to Screening. 
This is a 2- part study  in which up to a total of approximately  72 p articipants on SoC are 
planned to be enrolled .It is a randomized, double
-blind, sponsor -open, parallel group, 
placebo
-controlled trial. Part 1 is to evaluate safety , tolerability , and PK of escalating doses 
of PF -07304814 given as 24- hour IV infusions. Two planned and 3 optional cohort swith 
8participants/cohort will be inclu ded in Part 1: SAD (24-h continuous infusion).
Precautionary  sentinel dosing will be used in each dose -escalating cohort in Part 1 .A small 
cohort of 2 participants (1 receiving PF-07304814 and 1 receiving placebo) within a cohort 
will be dosed prior to th e remainder of the cohort. Part 2: MAD is to evaluate safety , 
tolerabi lity, and PK 
of multiple ascending doses of PF -07304814 given as 120-hour IV 
infusion
s.Two planned and 2 option al cohort swith 8 participants/cohort will be inc luded in 
Part 2.
Number of 
Participants
A maximum of approximately  72participants will be enrolled to study  intervention such that 
approximately  72evaluable participants complete the study .
Note: "Enrolled "means a participant's, or his or her legally  authorized representative’s, 
agreement to participate in a clinical study  following completion of the informed consent 
process. Potential participants who are screened for the purpose of determining eligibilit yfor 
the study , but do not participate in the st
udy, are not considered enr olled, unless otherwise 
specified b y the protocol.
Participants who discontinue during the trial for reasons other than drug-related safety  events 
may be replaced at the discretion of the Sponsor and I nvestigator .
Intervention Groups and Duration
Part 1: S ADCohorts of 8 participants each who meet the eligibility criteria will be enrolled.
The 2 sentinel participants will be randomized in a PF-07304814:placebo ratio of 1:1, while 
the
remaining 6 participants will be randomized in a ratio of 5 (PF-07304814 ) :1 (placebo ).
Both treatments will be administered in a telemetered (for 12 hours post the start of dosing) 
setting as a continuous IV infusion for 24 hours for each dose , in additi on to SoC therapy .
They  will be required to stay  inhospital from at a minim um, Day 1, pre -dose (at least 

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 202 0
PFIZER CONFIDENTIAL
Page 252hours) through completion of Day 3 evaluations (Follow -up 1). Participants will then return 
for Day  6 (Follow -up 2) activities and a plan ned final f ollow -up visit per the SoA on 
Day 30-37 (Follow - up 3) for a total of approximately  4-5 weeks study  participation from first 
dose to follow
-up, excluding screening. 
Part 2: MAD Cohorts of 8 participants each who meet the e ligibility criteria will be enrolled 
and randomized in a PF-07304814:placebo ratio of 6:2.Participants will be required to stay  
in hospital from, 
at a minimum, Day  1, pre -dose through completion of Day 7 evaluations 
(Follow -up 1). Participants will then return for D ay10 (Follow -up 2) and Day 14 
(Follow -up3) act ivities and a final planned follow -up (Follow -up 4) visit per the SoA on 
Days 34- 41 for a total of approximately  5-6weeks study  participation from the start of 
dosing to follow -
up, ex cluding screening.
Data Monitoring Committee or Other Independent Oversight Committee: IRC
This study  will use an IRC, which is independent of the study  team and includes Pfizer 
internal members. In Part 1, emerging data will be reviewed b ythe Investigat or(s) (if 
available) , the study  team and the IRC.The independent IRC will a ssess whether it is safe to 
proceed to continued dosing within a cohort following sentinel dosing and whether it is safe 
to dose-escalat e to the next dose level . The I RC may  also b econsulted at other times to 
review safet y data.
Statistical Methods
The sa mple size for both parts of the study  has been chosen based on the need to minimize 
first exposure to humans of a new chemical entity  and the requirements to prov
ide adequate 
safet yand toleration information at each dose level.
Safety data will be presented in tabular and/or graphical format and summarized 
descriptivel y, where appropriate. No formal anal yses are planned for safety  data.
PK parameters of PF -0730481 4 and PF-00835231 w ill be derived following 24- and 
120-hour infusi ons. The PK data for PF-073 04814 and PF -00835231 will be reported 
separately and will be listed and descriptively  summarized as required. No formal inferential 
statistics will be applied to the PK data.

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 202 0
PFIZER CONFIDENTIAL
Page 261.2.Sche ma
Overall Study Design of C4611001
Doses and dosingscheme presented are projected based on nonclinical data and may  be 
modified based on emerging safet y, tolerability, and PK data. Theprojected exposures 
(adjusted based on observed PK) at the modified doses as well as those for the optional 
cohorts wi ll not exceed the exposur e limits agreed with competent regulatory  authorities.

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 202 0
PFIZER CONFIDENTIAL
Page 27Part 1 :SAD (24-h Continuous IV Infusion )

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 202 0
PFIZER CONFIDENTIAL
Page 28Precautionary  sentinel dosing will be used in each dose -escalating cohort in P art 1. A small cohort of 2 participants (1 receiv ing 
PF-07304814 and 1 recei ving placebo) will be dosed prior to the remainder of the cohort. All available safet y and tolerability data 
from the 2 sentinel participants up to at least Day 3 at 24 hours post completion of dosing will be reviewed by  the Inve stigator(s) (if 
available) ,the study  team andIRC.The IRC will then determine whether it is safe to proceed to dose the remaining participants in the
cohort.
Part 2 : MAD (120h Continuous IV Infusion )

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 202 0
PFIZER CONFIDENTIAL
Page 362.INTRODUCTION
PF-073048 14 is a phosphate prodrug of PF -00835231, a potent and selec tive inhibitor of the 
SARS -CoV -2 3CL  protease, that is being developed as a continuous IV infusion for the 
treatment of patients hospitalized with COVI D
-19.
2.1.Study Rationale
The cur rent study  is th e first clinical administration with PF -07304814. It is desi gned as a 
2-part stud y in hospitalized COVID -19 patients as arandomized, double -blind, 
sponsor -open, parallel group, placebo -controlled tria l.Part 1 is to evaluate safet y, tolera bility, 
PK and m arkers of clinical activity  of escalating doses of PF -
07304814 given as 24 -hour IV 
infusions. Part 2 is to evaluate safet y, tolerability , PK and markers of clinical activity with
escalatin g doses of PF -07304814 given as 120- hour IV infusions.
2.2.Background
Disease Overview
In December 2019, COVID -19 was identified as a new, potentially  fatal, respiratory  infection 
caused b y the novel coronavirus, SARS -CoV -2.The WHO declared COVID -19 a Public 
Health Emerge ncy of International Concern on 20 January2020 and fur thercharacterized the 
disease outbreak as a pandemic on 11 March 2020.1
COVID -19 manifests as a wide range of illness, from asy mptomatic infect ion to severe 
pneumonia, ARDS and death. While the m ajority  of cases (approximately  80%) are 
asymptomatic or mild ,2patients who are hospitalized with COVID -19 may  have significant 
morbidity  and mortality ,3,4and are at increased risk of developin g complications such as 
severe inflammation associated with elevations in pro- inflammatory  cytokines, ARDS, ac ute 
cardiac injury , thromboembolic events, hy percoagulability , and/or kidney  injury.5-9
Current Treatment Options
As of December 2020, vaccine s are not yet widely  available to prevent in fection with 
SARS -CoV -2 and aside from sy mptomatic a nd/or supportive treatments there are fewdrugs 
approved and a vailable to tr eat COVID -19.As of June, 2020, only  1 anti -viral drug with 
activity  against SARS -CoV -2, Remdesivir , an RNA poly merase inhibitor , has shown clinical 
benefit in hospitalized patients with COVI D -19.10While additio nal data from studies of 
Remdesivir and other drugs are becoming available, published preliminary reports suggest 
that Remdesivir may not be sufficient as monotherapy  in all subset s of patients ac rossthe 
spectrum of disease.10Furthermore, Remdesivir is only  available on a limited basis, through 
emergency  use authorization in the US ,11authoriza tion for compass ionate use in the EU ,12
and approved in a small number of countrie s.13-15

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 202 0
PFIZER CONFIDENTIAL
Page 37The FDA has issued EUA to 2 monocl onal antibodies, bamlanivimab and the combinatio n 
casirivimab plus imdevimab, the drug baricitinab, in combination with remdesivir, and 
convalescent plasma for the treatment of COVID -
19. The use of monocl onal antibodies is
limited to the outpatient setting
in patients at hi ghrisk of progressing to severe disease and/or 
hospitaliz ation. At the time of the most recent update to the COVID -19 Treatment Guidelines 
Panel (03 December 2020) , the Panel did not be lieve there was su fficient data to recommend
any of these 4 therapeuti cs as part of the standard of care.
Inaddition, the gluc ocorticoid anti -inflammatory  dexamethasone has been recommended in 
the COVID -19 Treatment Guidelines Panel at NIH guidelines for the treatment of on the 
basis of the preliminary  report from the RE COVERY trial [DOI : 10.1056/NEJMoa2021436], 
for the treatment of COVID -19 in hospitalized patients who are mechanically  ventilated or 
who require supplemental oxy gen 
[https://www.covid19tre atmentguidelines.n ih.gov/immune -based -
therap y/immuno modulators/cortico steroids/].
In spite of these advances, there remains an u rgent need for additional safe and more 
effective therapeutic interventions that shorten time to clinical recovery  and prevent t he 
progression of infection to more severe disease a nd death. The di rectreduction of viral 
replication, through inhibition of o ther critical viral enzy mes, offers an important mechanism 
as monotherap y or in combination, to achieve greater patient benefit.
Rationale for Development of PF -07304814
The SARS 3CL  protease is a virally encoded enzyme that is critical to the SARS -CoV - 2 life 
cycle, analogous to other obligatory  virally  encoded proteases (eg, HIV Protease, HCV 
Protease).16Mutagenesis experiments with othe r coronaviruses an d picornaviruses that are 
related to SARS -CoV -2 (picornavi rus-like supercluster) have demonstrated that the activity  
of the 3
CL protein (or the corresponding picornaviral 3C enzy me) is e ssential for viral 
replication. No close human analo gs of the SARS 3 CLenzyme are known, suggesting that 
appropriate SARS 3CL  inhibitors may  function as selective anti -SARS and other 
coronaviruse s as therapeutic agents.
Inhibition of the SARS 3CL  protease is a mechanism of action distinct from that of 
Remde sivir, which is a prodrug of an adenosine nucleoside analogue that interfere s with 
SARS -CoV -2 RNA -dependent RNA poly merase. In vitro studies (s ee Section 2.2.1.1.1), 
indicate that the combination of PF -
00835231, the active moiety  of the phosphate prodrug of 
PF-07304814, and Remdesivir may have an additive effect with respect to inhibiting viral 
replication of SARS -CoV -
2.

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 202 0
PFIZER CONFIDENTIAL
Page 382.2.1. Non-clinical Overview
2.2.1.1. Non-clinical Pharmacology:
2.2.1.1.1. In vitro Pharmacology
PF-00835231 has been determined to be a potent and selective inhibitor of the SAR S 3CLpro. 
PF-00835231 inhibited the full length enzy me activity  of SARS -CoV -2 3CLprowith an IC 50
of 0.00692 
µM (Kiappof 0.0003 µM), and the prodrug, PF -07304814 inhibited the sam e 
enzy me with an IC50of 0.443 µ M (Ki of 0.174 µM), indicating the active mo iety 
PF-00835231 is >600- fold more active than the prodrug. PF ‑00835231 inhibited 
SARS -CoV -1 3CLprowith a Kiappof 0.0047 μM and inhibited the HCoV ‑229E 3CLprowith a 
Kiappof 0.0012 µM.
For the PF -07304814 development program the antiviral activity  of the active moiety , 
PF-00835231 and the prodrug, PF- 07304814 were assessed in several in vitro SARS -CoV -2 
assay s within different laboratories as summarized in Table 1.
Table 1. Assay Conditions to Asse ss the Antiviral SARS -CoV -1 and SARS -CoV -2 
Activity of PF -07304814 and PF-00835231
Assay Location
Assay 
Param etersNYUaNYUbSRIcRegadScrippse
Virus strain USA -WA1/2020 Washington SARS -CoV- 1 
(Toronto 2); 
SARS -CoV- 2 
(USA-
WA1/2020)SARS -CoV- 1 
(20030059 2-
Vietnam); 
SARS -CoV- 2 
(BetaCov 
GHB -03021/2020 )USA -
WA1/2020
Cell type A549 -ACE2 Human primary 
HAEVeroE6 -ACE2 
enrichedVeroE6 -EGFP HeLa -ACE2
Cell origin Human
lungHuman
lungMonkey 
kidneyMonkey
kidneyHuman
cervical
Duration 24, 48 hours 24, 48 hours 3 days 5 days 24 hours
End point Viral protein Virus 
productionCPE CPE Viral protein
Detection Immunofluor 
imagingPlaque assay CTG Fluor imaging Immunofluor 
imaging
a.Experiments conducted at New York University Langone School of Medicine.
b.Experiments conducted at New York University Langone School of Medicine.
c.Experiments conducted at Southern Research Institute in Birmingham, Alabama.
d.Experiments conducted at Rega Institute, Leuven, Belgium.
e.Experiments conducted at Scripps Research Institute.
These assay s are representative of the current antiviral assessments being used in the field to 
date. The antiviral activities in the physiologicall y relevant human lung derived cell line, 
A549 -ACE2 with a direct viral readout were used as an approximation for C effselection 
purposes. The antiviral activity  of PF -00835231 and Remdesivir (as a control ) were 
evaluated against SARS- CoV -2 A5 49-ACE2 cells as summarized in Table 2.

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 202 0
PFIZER CONFIDENTIAL
Page 39Table 2. Summary of PF-00835231 and Remdesivir Inhibition of SARS -CoV -2 
Expression in A549- ACE2 Cells
Time post 
infectionEC 50µMa
(95% CI)EC 90µMa
(95% CI)CC 50µMa
(95% CI)TIb
PF-00835231
24 Hours 0.221
(0.137 to 0.356)0.734
(0.391 to 1.38)>10
(ND)>46
48 Hours 0.158
(0.079 to 0.314)0.439
(0.380 to 0.508)>10
(ND)>65
Remdesivir
24 Hours 0.442
(0.240 to 0.814)1.19
(0.622 to 2.28)>10
(ND)>23
48 Hours 0.238
(0.122 to 0.463)0.592
(0.534 to 0.656)>10
(ND)>43
a.Value is the geometric mean (n=3).
b.TI calculated as: CC 50/EC 50.
The inhibitory  activity  of PF -00835231 on SARS -CoV -2 in A549 -ACE2 cells was c onfirmed 
by data from polarized human airway  epithelial (HAE) cells. PF-00835231 maintains the 
potent inhibition of SARS -CoV -2 virus production at 0.025, 0.5, and 10 μM from vario us 
time points with the most significant reduction of 8 -, 30- and 2940 -fold, respectivel y, at 
48hours post -infection (data not shown )with simila r results for Remdesivir , tested in 
parallel as a control. These preliminary  results provide an indication that the compound 
activity  in this model is similar to what was observed for the A549 -ACE2 assay .
The anti -SARS -CoV -2 activity  of PF -00835231 was sup ported b y data from another human 
cell line albeit of a different organ origin. In He L
a-ACE2 cells, PF -00835231 inhibited 
SARS CoV2 replication at an a verage EC 50/EC 90of 0.144 µ M/0.398 µ M,in line with results 
in A549- ACE2 cells (Table 3).
Table 3. PF-00835231 and Remdesivir inhibition of SARS CoV2 expression in 
HeLa -ACE2 cells
EC50µM
(95% CI)EC90µM
(95% CI)
PF-00835231a
0.144
(0.074 to 0.278)0.398
(0.143 to 1.10)
Remdesivirb
0.074
(0.063 to 0.087)0.168
(0.108 to 0.250)
n = number of replicates .
a.Values are the geometric mean (n=3).
b.Values are the geometric mean (n=4).

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 202 0
PFIZER CONFIDENTIAL
Page 40In addition, for comparative purposes we generated efficacy  data in VeroE6 cells as SARS 
antiviral assay s are t ypically perform ed in Vero cells which support high levels of SARS 
replication . However, they are not considered as relevant as A549 -ACE2 due to the fact they  
are not of human origin (African gree n monkey ) as well as derived from a different organ 
type (kidney ).In additi on,contrary  to the virus target cells in lung and bronchus, Vero cells 
are known to express high levels of P -gp, a multi -drug resistance protein that pumps 
xenobiotics out of cell s.17Since PF ‑00835231 is a P -gpsubstrate, anti -viral screening in this 
cell ty pe was done with and without the presence of a P -gp EI, CP-100356. T he levels of 
P
-gp expression in the cells used in SARS -CoV -2 antiviral assay s were analy zed. P-gp was 
shown to be expressed to much higher levels (>380 fold) in Vero76, VeroE6, VeroE6 
enriched for hACE2, VeroE6 stabl y expressing EGFP than the ph ysiologically  relevant 
A549 cells as well as HeLa cells. Data from different labs using Vero cells showed that 
PF-
00835231 a lone had significantl y higher EC 50values than in the presence of 0.5 µM EI.
This observation of PF -00835231 inhibition was reproduceable in tests using VeroE6 cells or 
VeroE6 cells expressing EGFP. Furthermore, increasing the concentration of the EI from 
0.5to 2µMwhen P -gp activity appears sufficiently  suppressed , EC 50levels in VeroE6 cells 
are at the similar level as in A549 cells (Table 4).

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 202 0
PFIZER CONFIDENTIAL
Page 41Table 4. Summary of the In Vitro Antiviral Activity, Cytotoxic ity, and TI for PF-00835231 With and Without the P -gp 
Efflux Inhibitor, CP
-100356
Virus Strain Host Cell PF-00835231 ± EI EC50 µM CC50 µM TIa
Geometric Mean (95% CI) n Geometric Mean n
SARS -CoV-2 VeroE6b-EI (0 µM) 88.9c76.8 to 103 5 >100c8 >1.2
+ EI (0.5 µM) 8.21c 3.12 to 21.6 8 >100c 8 >21
+ EI (2 µM) 0.760c 0.449 to 1.29 4 >50c 4 >32
VeroE6d-EI (0 µM) 39.8c 29.8 to 53.2 10 >100 9 > 2.5
+ EI (0.5 µM) 2.93c 1.13 to 7.64 7 >100 6 >35
+ EI (2 µM) 0.236c 0.135 to 0.412 6 >100 6 >400
SARS -CoV-1 Vero76e-EI (0 µM) 5.0 3.1 to 8.1 4 ≥208f5 >42
+ EI (0.5 µM) 0.11 ND 2 >100 2 >900
VeroE6g-EI (0 µM) >100 ND 6 >100 6 ND
+ EI (0.5 µM) 10.8c 3.80 to 30.8 6 >100 6 >11
VeroE6h-EI (0 µM) 93.8c ND 1 >100 2 >1.1
+ EI (0.5 µM) 1.91c 0.701 and 5.18i2 >100 2 >45
HCoV -229E j MRC -5 - EI (0 µM) 0.088 0.047 to 0.160 16 ≥208f6 ≥2300
+ EI (0.5 µM) 0.19 ND 1 >1 1 >5.3

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 202 0
PFIZER CONFIDENTIAL
Page 42MRC -5 -EI (0 µM) 0.0692 0.0561 to 0.0852 7 >100 5 >510
+ EI (0.5 µM) 0.0795 0.0169 to 0.373 3 >100 3 >770
Huh7 -EI (0 µM) 0.0909 0.0638 to 0.129 4 >100 4 >480
+ EI (0.5 µM) 0.0778 0.0316 to 0.192 3 >100 3 >1300
a. The TI was calculated by dividing CC 50/EC 50.
b. SARS -CoV -2 (EPI ISL 407976| 2020 -02-03/BetaCoV/Belgium/ GHB03021/2020) strain.
c. EC 50curves were fit to a Hill slope of 3. If cytotoxicity was detecte d at >30% effect, the corresponding concentration data was eliminated for the determination of EC 50.
d. SARS -CoV -2 (USA_WAI/2020_TVP23156) strain.
e. SARS -CoV -1 Toronto 2 strain.
f. PF-00835231 solubility in assay media, pH 6.5 was 208 uM.
g. SARS -CoV -1 (200300592 -Vietnam).
h. SARS -CoV -1 Toronto 2 strain.
i. Values listed are the 2 values (when n=2); not the CI.
j. HCoV -229E is ATCC strain.

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 202 0
PFIZER CONFIDENTIAL
Page 43The antiviral activit ydata of PF -00835231 against SARS -CoV -2 in the various tested cell 
lines of different origins are consistent, includ ing in the unrelated monkey  kidney  derived 
Vero cells when its P -gp activity  was sufficientl y suppressed. The EC 50value 
of ~0.25 µ M 
and EC 90value of ~0.5 µ M derived from the physiologicall yrelevant A549 -ACE2 human 
lung carcinoma cells are supported by  data from other cell lines, demonstrating a consistent 
intrinsic potency against SARS -CoV -2.
To understand the activity of PF-
00835231 against other coronaviruses in human cell lines 
(normal human lung epithelial cells [MRC -5] and human hepatocellular carci noma cells 
[Huh7]), the compound was tested for antiviral activity  against an alpha coronavirus, 
HCoV -229E, which naturally  circulates among 
humans. Anti- viral activity  was observed 
with the compound potently  inhibiting HCoV -229E -induced cy topathic effects in both cell 
lines, demonstrating EC 50values ranging from 0.069 to 0.190 µ M regardless of the presence 
of the 
EI(Table 4).In contrast to Vero cell assay s, the presence of an EIdid not enhance 
PF-00835231 activit y, consistent w ith the known lack of P -gp activity  in MRC -5 cells.18
PF‑00835231 binds to the active site of both SARS -CoV -1 and SARS -CoV -2 3CLpros, as 
determined b y X-ray co-crystal structures. Both structures are consistent with a covalent and 
reversible interaction of PF -00835231 at the active site catal ytic cy steine res idue of each 
3CLpro, thus inhibiting the activity  of the protease. PF-00835231 was also determined to be 
active against several other human coronavi rus 3CLpro, including that of MERS, 
HCoV -OC43, HCoV -HKU1, and HCoV- NL63. This pan -coronavirus 3CLproinhibit ion could 
be explained by  the similarity  of 3CLproacross the Coronaviridae family  where critical amino 
acid residues involved in enzy me-inhibitor binding interactions are particularly  well 
conserved. For example, PF‑00835231 interacts only  with the side c hains of coronavirus 
3CLproamino acids that are completel y conserved between SARS -CoV -1 and SARS -CoV -2.
Further details may  be found in the IB.
2.2.1.1.2. In vivo Pharmacology
Studies on in vivo pharmacology  of PF-07304814 or PF -00835231 have not been reported. 
However , some in vivo model studies have been complete d the in - life phase and a 
preliminary  anal ysis is shown below.  
The mouse is not a natural host of SARS -CoV -2 or CoV-1. Although mice have the ACE2 
receptor, it is sufficiently different from the human version of ACE2 such that the viruses are 
unable to infect mice. However, b y passage of SARS -CoV -1 virus multiple times in mice, 
the virus Spike (S) protein adapts to enable utilization of the mouse recep tor. Mutations were 
present in 3CL  protease coding sequence of the mouse -adapted CoV -1 strain, but they  were 
distant from the active site which is 100% identical between CoV -1 and CoV -2. The 
resulting virus can infect mice and cause disease, which is chara cterized b y weight loss and 
lung pathology  that are consistent with human disease. The virus also replica tes to high 
levels in the lungs of the mice. This mouse -adapted model of CoV-1 infection was used to 
evaluate PF -00835231 (the parent molecule to the prodrug, PF -07304814). The experiments 
are on -going. To summarize, mice that were infected with mouse -adap tedCoV -1 were 

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 202 0
PFIZER CONFIDENTIAL
Page 44treated with PF -00835231 at 100 mg/kg, twice daily  (BID) by  the SC route. This is a dose 
that was predi cted to give an exposure of the d rug at C minof approximately 500nM or about 
EC 90. In one experiment, treatment was initiated at the time of infection ( Day 0) or delay ed 
for 1 -or 2-days post -infection. Viral titers in the lung were reduced ~ 2.0, 1.5 and 1.0log 10
with treatment starting on Days 0, 1, and 2 post -infection, respectivel y. Weight loss and 
histopathologic signs of disease were decreased, particularl y when dosing of PF -00835231 
was started on D ay 0. In a second experiment, treatment with PF -00835231 was initiated on 
Day0 and the dose of drug was varied (30, 100, 300 mg/kg, BID, SC). A dose -dependent 
decline in viral titers in the lung was observed for the three doses: ~ 1.5 log 10at 30 mg/kg; 
~3log 10at 100 mg/kg; and ≥ 3.5 log 10at 300 mg/kg. The decline in weight loss caused b y the 
virus was reduced b y treatment with PF
-00835231 at all doses compared to infected, 
untreated mice . The drug exposure at 300 mg/kg in this experiment was 3-4-foldhigher than 
that observed pr eviously  with 100 mg/kg. Histopathology  for this experiment is not available 
currentl y.
2.2.1.2. Nonclinical Pharmacokinetics and Metabolism
2.2.1.2.1. Nonclinical Pharmac okinetics and Prediction of Human Pharmacokinetics
Preliminary  human in vitro metabolism data indicate PF -07304814 is rapidly  metabolized by  
alkaline phosphatase in the liver forming the active metabolite PF -00835231. Both 
PF-
07304814 and PF- 00835231 exhib it similar metabolic profiles in rat, dog, monkey and 
human liver microsomes with no human specific metab olites observed.
Overall, based on human vitro and animal in vivo data the major clearance pathway  for 
PF-00835231 is predicted to be via CYP3A4 metabo lism (fm 0.76) with minor contributions 
from additional CYPs (fm 0.12) and via renal clearance (fm 0.12).
Preliminary  assessments based on in vitro DDI studies and the predicted s ystemic exposure 
in humans following the projected efficacious dose indicate a low potential for DDI due to 
PF-07304814 or PF- 00835231 mediated inhibition of CYP1A2, 2B6, 2C19, 2C8, 2C9, 2D6 
and CYP3A4. PF-00835231 demonstrated weak time -dependent inhibition of CYP3A.
There are potential DDI risks of PF- 00835231 as a substrate when co-administered with 
strong inhibitors and inducers of CYP3A4. Preliminary  SimCYP modeling indicated an 
approximate 2× or 0.5× change in PF -00835231 AUC when co- administered with a strong 
CYP3A4 inhibitor (eg, itraconazole) or strong inducer (eg ,rifampin ), respectively .At the 
predicted target C eff(Section 2.2.1.2.2 ) exposure, PF -07304814 and PF- 00835231 have a low 
potential as a perpetrator for enzy matic or transporter based DDIs. As higher doses are 
explored (ie, 10× the C eff), PF -00835231 has the po tential to time -dependently  inhibit 
CYP3A (up to 3 × AUC increase using midazolam as a probe substrate), and a potential for a 
transporter DDI b y inhibition of P -gp, BCRP, OATP1B1/1B3, OCT1, and MATE1/2K.
In humans the predicted CL pof PF -07304814 is ~10 mL /min/kg, Vd ssof 0.1 L/Kg and 
effective t ½~0.1 hour and the predicted CL pand V ssof PF ‑00835231 are 6 mL /min/kg and 
1L/kg respectivel y, providing an effective t ½of approximately  2 hours.

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 202 0
PFIZER CONFIDENTIAL
Page 47tolerability  of 24h and 120h infusions of PF-07304814 in these populations, the sponsor 
proposes a Phase 2/3 adaptive design efficacy  study  in hospitalized COVID -
19 pa tients 
(C4611002).
Asof 18November, 2020, 4 patient participants in Cohort 1 received a single dose of 
PF-07304814 or placebo , administered as a 24 -hour continuous IV infusion in the study  
C4611001. Based on emerging PK data in participants who receive d PF- 07304814, dosing in 
Cohort 1 (500 mg dose) was stopped and dosing in a new cohort , Cohort
3,at 250 mg was
initiated. As of 16 December, 20 20, three participants in Cohort 3 have been dosed with 
either PF -07304814 or placebo.
2.2.2.1. Study C4611007 -Ongoing
This is the second clinical administration with PF -
07304814, but first in healthy  adult 
participants
. This is a Phase 1, randomized, double -blind, sponsor open (ie, participant blind, 
investigator blind and sponsor open), placebo -controlled SAD study , with ongoing review of 
safet y, tolerabilit y, and PK .
There are 2 interleaving cohorts with a total of approximately  16participants (approximately  
8participants in each cohort), with 2-period cross- over in each cohort . For each period, 
approximately  6 pa rticipants will have receive da single dose of PF -07304814 administered 
as a 24 h continuous IV infusion, and a pproximately  2participants will have receive d
placebo. Each participant may have receive d either a single dose of PF- 07304814 or a 
placebo durin g eachperiod.
The nominal doses of PF -07304814 are 50mg,150mg, 500 mg, and 700mgfora 24h
continuous infusion. In addition to standard safet y assessments ,hsCRP, D-dimer, and 
coagulation pa nel (aPTT, PTT) are moni tored 
to evaluate an y potential pro -inflammatory  or 
hypercoagulable effect of study  intervention . 
The study  began in Oct ober 2020, and at the time of the data cutoff date 21 November 2020,
safet y data from last planned safet
y labs (Day 5) from the las t participant was reviewed.
There were 20 TE AEs reported by  12 participants. All of the TEAEs were categorized as
mild in severity . One AE of injection site pain, reported as mild in severit y, was considered 
treatment related b y the investigator. For the d
escription of each AEs please refer to the I B
(December 2020). There were no deaths, serious AEs (SAEs), severe AEs, or 
discontinuations due to AEs during the study .
There were no individual laboratory  abnormalities assessed as clinica lly significant by  the 
investigator. Across the treatment groups there were no clinicall y significant c hanges in the 
inflammatory  marker, hs
-CRP. Tests evaluating the coagulation s ystem, aPTT, PT, 
fibrinogen and D -dimer ,were similarl y without clinically  significant changes over time. No 
participant developed a value th atwas clinically  significantly  elevat ed or outside the normal 
range . Overall, there was no evidence of a pro -inflammatory  effect clinically  or based on 
laboratory  results, at all dose levels.

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 202 0
PFIZER CONFIDENTIAL
Page 48Preliminary  pharmacokinetic (PK) data following single dose 24h continuous I V infusion 
at50, 150, 500 and700 mg are included in this update with a data cut- off date of 
21November 2020.
Maximum or near maximum plasma concentrations of the active moiet yPF-00835231 were 
generall y first observed ~6h post start of the infusion and sustained unti l the end of the 
infusion. PF -00835231 plasma concentrations declined rapidly  afterwards. T he t½values 
were onl y reportable at 500 and 700 mg and were 2.25 h
ourand 2.02 h our, respectivel y. 
Mean C maxand AUC values appeared to i
ncrease in a dose proportio nal manner in the dose 
range tested. 
Maximum or near maximum plasma concentrations of the phosphate prodrug PF-07304814 
were generally  first observed ~3h and susta ined until at least 16h post start of the infusion. 
Despite conti nuous infusion of the prodr ug and sustained plasma concentration of the active 
moiety , the concentration of PF -07304814 declined before the end of the infusion. T
he 
t½values could not be det ermined since all plasma samples collected after the 16h post sta rt
of the infusion were BLQ s of 40 ng/mL . While the mean C maxvalues appeared to increase in 
a dose proportional manner in the dose range tested, the AUC values appeared to increase in 
a slig htly greater than dose proportional manner.
More detailed inform ation may  be found in the 
latest IB(December, 2020) .
2.3.Benefit/Risk Assessment
More detailed information about the known and expected benefits and risks and reasonabl y 
expected AEs of PF-07304814 may be found in the latest IB(December, 2020) , which is the
SRSD for this study .

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 202 0
PFIZER CONFIDENTIAL
Page 50Potential Risk of Clinical Significance Summary of Data/Rationale for 
RiskMitigation Strategy
Central venous catheterization or midline 
use for blood draws (not required b y the 
protocol) .Central venous catheterization or 
midline, although not required by  
the protoc ol, may  be indicated in 
some cases according to local 
standard of care and may lead to 
increased risk of DVT in some 
patients.
As of 16-Oct- 2020, 2 participants 
in sentinel dosing group o f 
Cohort 1 e xperience d DVT in the 
arm where a midline was 
inserted. 
One participant received 
the study  drug PF -07304814 and 
the other received placebo. The 
placebo and stud y drug were not 
infused through the midline.Appropriate anti -coagulant prophy laxis
administration shoul d be considered as per local 
guidelines.
Potent ial for increased risk of intravenous 
infusion site reaction.There may  bepotential riskof 
infusion site reaction due to low 
pH of study  intervention and/or 
need for continuous intravenous 
infusion. - These risks are 
described in the SRSD for 
PF-07304814.Monitoring of infusion site reactions will be 
performed through targeted PE and collecti on of 
AEs, which will be reviewed on an ongoing basis. 
Infusion solution may  be diluted.
Other
Not applicable.

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 2020
PFIZER CONFIDENTIAL
Page 534.STUDY DESIGN
4.1.Overall Design
This is a First -In-Human Phase 1b study  to evaluate the safety , tolerability and PK of 
PF-07304814 in participants who are hospitalized for treatment of COVID-19. The 
participa ntswill be receiving SoC therap y for the treatment of mild, mode rate, or severe 
COVID -19, but will not be eligible if they  require mechanical ventilation or ECMO at 
screening 
orbaseline. All participants will have a confirmed positive test for SARS -CoV -2
(see Section 5.1 for additional details) and onset of sy mptoms within 15 day s of Screening .
For inclusion into Part 2: MAD of the study , participants will be required to have had a 
positive test for SARS -CoV-2 (See Section 5.1for details) within 72 hours prior to 
Screening . 
This is a 2- part study  in which up to a tota l of approximately  72participants on SoC with the 
intervention such that approximately  72evaluable participants complete the study .It is a 
randomized, double -blind, sponsor -open, parallel group, placebo -controlled trial. 
Part 1:SAD is to ev
aluate safet y, tolerability, and PK of escalating doses of PF -07304814 
given as 24- hour IV infusions. Two planned and 3optional cohort swith 8 participants/cohort 
will be included in Part 1. Part 2: MAD is to evaluate safet y, tolerability , and PK of 
multiple ascending doses of PF -07304814 given as 120- hour IV infusion s.Two planned a nd 
2 optional cohort swith 8 participants/cohort will be included in Part 2 .
4.1.1. Part 1: SAD 
Precautionary  sentinel dosing will be used in each dose -escalating , ie, increasing dose,
cohort in Pa rt 1.A small cohort of 2 participants (1 receiving PF -07304814 and 1 receiving 
placebo) 
will be dosed prior to the remainder of the cohort. All available safety  and 
tolerability  data from the 2sentinel participants up to at least Day  3 at 24 ho urs post 
completion of dosing will be reviewed b y the Investigator(s) (if available) , the study  team 
and I RC.The independent IRC will then determine w hether it is safe to proceed to dose the 
remaining participants in the cohort.
Cohorts of 8 participants each who meet the eligibility  criteria (see Section s 5.1 and 5.2) will 
be enrolled. The 2 sentinel participants will be randomized in a ratio of 1 (PF- 07304814) : 
1
(placebo ), while the remaining 6 participants will be randomiz ed in a ratio of 
5
(PF-07304814):1 ( placebo ) . Both treatments will be administered in a t elemetered (for 
12hours post the start of dosing) setting as a continuous I V infusion for 24 hours for ea ch 
dose, in addition to SoC therap y.
All participants will fo llow the study  procedures as outlined in Section 1.3, SoA.They  will 
be required to stay in hospital from 
at a minimum, Day 1, pre -dose (at least 2 hours) through 
completion of Day 3evaluations (Follow -
up 1). Participants will then return for Day 6 
(Follow -up2) activities and a planned final follow -upvisit per the SoA on Day 30-37
(Follow -
up3) for a total of approximately  4-5weeks study  participation from first dose to 
follow -up, excluding screening. 

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 2020
PFIZER CONFIDENTIAL
Page 54Participants who discontinue for reasons other than drug-related safety  events during the trial 
may be replaced at the discretion of the Sponsor and investigator .
Three optional cohort s may  be added t o further explore thedose range based on emerging 
safet y
,tolerabilit y and PKassessments. However, the projected exposures at the top dose 
(adjusted based on observed PK) in Part 1: SAD will not exceed the exposure limits agreed 
with competent regulatory authorities.
After reviewing emerging safet y, tolerabilit y, and PK data ( Section 6.6.1) by  the study  team,
the Investigator (s)(if available) and IRC , the decision to proceed to the next dose level will 
be made.
4.1.2. Part 2: MAD
Progression to Pa rt 2will o ccur if safet y, tolerability , and PK data from the Part 124-h 
infusion cohorts as well as those from study  C4611007 are determined to be supportive and 
acceptable b y competent regulatory  authorities
.The dose progression will be based on 
emerging PK , safe ty and tolerability  data and willnot exceed the exposure limits agreed with 
competent authorities . 
Cohorts of 8 participants each who meet the eligibility  criteria (see Section s
5.1and 5.2) will 
be enrolled and randomized in a ratio of 6 PF -07304814:2 placebo. All participants will 
follow the study  procedures as outlined 
in SoA.They  will be required to stay  in hospital from 
at
a minimum, Day 1, pre -dose through completion of Day 7 evaluations (Follow - up 1).
Participants will then return for Day 10 (Follow -up 2) and Day 14 (Follow -up 3) activities 
and a final planned follow -up(Follow -up 4) visit per the SoA on Day s 34-41 for a total of 
approximately  5-6weeks study  participation from the start of dosing to follow -up, excluding 
screening.
Participants who discontinue for reaso
ns other than drug-related safety  events during the trial 
may be replaced at the discretion of the Sponsor and investigator.
4.2.Scientific Rationale for Study Design
This study  will provide data on safety , tolerability , PK, biomarker changes and measures of 
disease activity in hospitalized patients infected with SARS -CoV -
2.Since this is a first in 
human study , patients who require mechanical ventilation or suf fer from severe, uncontrolled 
co-morbidities will be excluded to balance potential risk versus benef it.Risk is further 
mitigated b y a single dose escalation design in Part 1: SAD , with extensive assessment of 
safet y and PK. Precautionary  sentinel dosing w ill also be used in each dose -escalating cohort 
in Part 1 . A small cohort of 2 participants (1 recei ving PF -07304814 and 1 receiving 
placebo) will be dosed prior to the remainder of the cohort. An independent IRC will assess 
whether it is safe to proceed t
o continued dosing within a cohort following sentinel dosing or 
whether it is safe to dose-escalat e to the next dose level. In Part 2, PF -07304814 will be 
administered for a period 
of 5 day sof continuous infusion at a dose based on emerging data 
and with the agreement of the competent regulatory  authorit y.The potential for PF -07304814 

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 2020
PFIZER CONFIDENTIAL
Page 603.Participants with pre -existing moderate to severe or poorly  controlled cardiovascular 
disease including hy pertension or diabetes, 
or moderate to severe or poorl y controlled 
chronic lung disease s, including asthma or chronic obstructive pulmonary  disease , as 
assessed b y the investigator .
4.Participants with a known medical history  of ischemic heart disease, heart failure, 
dysrhythmia or other pre -existing cardiac condition that in the opinion of the 
investigator may  confuse interpretation of ECG or cardiovascular findings.
5.Participants with a known medical history  ofrecent acute or chronic liver disease (other 
than non -alcoholic hepatic steatosis), including chronic or active hepatitis B or C 
infecti on, or primary  biliary  cirrhosis .
6.Participants with history  of venous thromboembolic event, including deep venous 
thrombosis or pulmonary embolism. 
7.Participants with known HIV infec tion who have a CD4+ cell count <500/mm3and/or 
who are receiving a boost ed anti -retroviral treatment regimen.
8.Participants with a known medical history  of recurrent seizure s.
9. C onfirmed concurrent active sy stemic infection other than COVID -19.
10.Current diag nosis of cancer, unless in remission and untreated.
11.Other medical or psy chiatric condition including recent (within the past year) or active 
suicidal ideation /behavior or laboratory  abnormality  that may  increase the risk of study  
participation or , in the i nvestig ator’s judgment ,make the participant inappropriate for 
the study .
Prior/Concomitant Therapy:
12.Participant is receiving any medications or substances that are s trong inhibitors or 
inducers of cy tochrome P450 (CYP) 3A4.
13.Participant has received system ic oral, intravenous, or intramuscular corticosteroid 
therap y (>40 mg/day  equivalent prednisolone) within the previous 28 day s, except as 
required for COVID- 19 treatment .
14.Female participant who are taking hor monal therapy for contraception or as estrogen 
replacement therap y, post menopause. 
Prior/Concurrent Clinical St udy Experience:
15.Previous administration with any  investigational drug within 30 days (or as determined 
by the local requirement) or 5 half-lives preceding the first dose of investigational 
product used in this study  (whichever is longer) .

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 2020
PFIZER CONFIDENTIAL
Page 61Note : Participant s are allowed to participate if receiving local standard of care for 
COVID -19 including Remdesivir, convalescent sera/plasma, monoclonal antibody  
treatments . Participation in an open -label investigational/observational study  for 
convalescent serum /plasma is also allowed so long an y associated stud y procedures do 
not, in the opinion of the investigator ,interfere with the current study .If other therapies 
receive Emergency  Use Authorization s tatus, th eymay also be allowed after discussion 
with the sponsor.  
Diagnostic Assessments:
16.Screening 12- lead ECG that demonstrates clinically  relevant abnormalities that may  
affect participant safet y or interpretation of stud y results (eg, baseline QTcF interval 
>450 msec, complete LBBB, signs of an acute or indeterminate -age m yocardial 
infarction, ST -T interval changes suggestive of my ocardial ischemia, second -or 
third- degree AV block, or serious b rady-arrhy thmias or tachy arrhy thmias).
If QTcF exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be 
repeated 2 more times and the average of the 3 QTcFor QRS values should be 
used to determine the participant’s eligibility .Computer -interpreted EC Gs should 
be overread b y a physician experienced in read ing ECGs before excluding 
participants.
17.Participants with any  of the following abnormalities in clinical laboratory  tests at 
screening, confirmed b y a single repeat test, if deemed necessary :
AST or A LT level ≥3 times the ULN .
Total bilirubin level ≥ 1.5 times the UL N, unless due to known Gilbert’s 
syndrome .
CL cr<60 mL/min using the Cockcroft -Gault equation .
Absolute neutrophil count < 1000/mm3.
Other Exclusions:
18.Females who are pregnant or 
breastfeeding .
19. Invest igatorsite staff or Pfizer employ ees directl y involved in the conduct of the study , 
site staff otherwise supervised by  the investigator, and their respective family  members .

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 2020
PFIZER CONFIDENTIAL
Page 625.3.Lifestyle Considerations
5.3.1. Contraception
The investigator or his or her designee, in consultation with the participant , will confirm that 
the participant has selected an appropriate method of contraception for the individual 
participant and his or her partner(s) from the permitted list of contraception methods (see
Appendix 4: Contraceptive Guidance , Section 10.4.4 )and will confirm that the participant
has been instructed in its consistent and correct use. At time points indicated in the SoA, the 
investigator or designee will info rm the participant of the need to use highly  effective 
contraception consistently and correctl y and document the conversation and the participant ’s 
affirmation in the participant ’s chart ( participant s need to affirm their consistent and correct 
use of at l east 1 of the selected methods of contraception). In addition, the investigator or 
designee will instruct the participant to call immediately  if the selected contraception method 
is discontinued or if pr egnancy  is known or suspected in the participant or partner.
5.4.Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study  but 
are not subsequently  assigned to study  intervention .A minimal set of screen failu re 
information is required to ensure transparent reporting of screen failure participants to meet 
the CONSORT publishing requirements and to respond to queries from regulatory  
authorities. Minimal information includes demography , screen failure details, el igibility  
criteria, and an y SAE.
Individuals who do not meet the criteria for participation in this study  (screen failure) may  be 
rescreened once onl y
.All screening assessments must be repeated during re -screening .
5.5. Criteria for Temporarily Delaying Enrol ment /Randomization/Study Intervention
Administration 
Not applicable .
6. STUDY INTERVENTION
Study  intervention is defined as any  investigational intervention(s), marketed product(s), 
placebo, medical device(s) , or study  procedure(s) intended to be administere d to a study  
participant according to the study  protocol.
For the purposes of this protocol, study  intervention refers to PF-07304814 or placebo .
6.1.Study Intervention(s) Administered
6.1.1. Administration
Study  intervention administration details will be recorded on the CRF Study Intervention(s) 
Administered .
The IV will be administered on the contralateral arm from PK sampling .

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 2020
PFIZER CONFIDENTIAL
Page 63The study  interventions are:
Part 1: SAD
PF-07304814 : treatment duration = 24-hour continuous intravenous infusion. Study  
intervention wil
l be provided as a solution for infusion in a vial. Vials are for single 
use in a single participant for a single dose.
Placebo: treatment duration = 24-hour continuous intravenous infusion .
Part 2: MAD
PF-07304814: treatment duration = 120 -hour continuou
sintravenous infusion. Study  
intervention will be provided as a powder in vial for solution for infusion. Vials are 
for single use in a single participant for a single dose .
Placebo: treatment duration = 120- hour continuous intravenous infusion.
Interventi onName PF-07304814 Solution for 
InfusionPF-07304814 Pow der for 
Solution for InfusionPlacebo
ARM Nam e
(group of patients 
receiving a specific 
treatm ent (or no 
treatm ent)PF-07304814 PF-07304814 Placebo
Type Drug Drug Placebo
Dose Form ulation Solution for infusion in a 
vial. 
Vial is single -use onlyPowder in a vial for 
solution for infusion .
Vial is single -use onlySolution for infusion in 
acommercial 
presentation i n IV bag
Unit Dose Strength(s) 250 mg as a 25 mg/mL 
solution1000 m g 0 mg
Dosage L evel(s) Planned nominal dose over 
24h continuous infusion in 
Part 1: 
Cohort 1: 500mg
Cohort 2: 1000 m g single 
dose over 24h.Planned nominal dose 
over 120h continuous 
infusion in Part 2: 
Cohort 6: 250 mg/day 
x 5days
Cohort 7: TBD
Only used in Part 2.Part 1: 24h
Part 2: 120h
Route of 
AdministrationIntravenous Intravenous Intravenous
Use Experimental Experimental Control
IMP or NIMP IMP IMP NIMP
Sourcing Provided centrally by the 
sponsorProvided centrally by the 
sponsorProvided locally by the 
trial site, subsidiary, or 
designee.

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 2020
PFIZER CONFIDENTIAL
Page 64Interventi onName PF-07304814 Solution for 
InfusionPF-07304814 Pow der for 
Solution for InfusionPlacebo
Packaging and 
LabelingStudy intervention will be 
provided in vials. Each vial 
will be labeled as required 
per country requirement. 
Please see IP manual for 
additional details.Study intervention will 
be provided in vials . 
Each vial will be labeled 
as required per country 
requirement. Please see 
IP m anual for additional 
details for preparation 
and blinding.Placebo will be 
provided by the trial 
site in commercial IV 
bags and prepared 
according to the IP 
manual. Please see IP 
manual for additional 
details.
Current/Former 
Nam e(s) or Alias(es)PF-07304814 PF-07304814 Placebo
6.2.Preparation/Handling/Storage/Accountability
1. The investigator or designee must confirm appropriate temperature conditions have 
been maintained during tra nsit for all study  intervention sreceived and an y 
discrepancies are reported and resolved before use of the study  intervention.
2.Only  participants enrolled in the study  may  receive study  intervention and only  
authorized site staff may  supply  or administer stud y intervention. All study  
intervention smust be stored in a secure, environmentally  controlled, and m onitored 
(manual or automated recording ) area in accordance with the labeled storage 
conditions with access limited to the investigator and authorized s itestaff. At a 
minimum, daily  minimum and maximum temperatures for all site storage locations 
must be documented and available upon request. Data for nonworking day s must 
indicate the minimum and maximum temperatures since previousl y documented for 
all si te storage locations upon return to business.
3.Any excursions from the study  intervention label storage c onditions should be 
reported to Pfizer upon discovery  along with an y actions taken. The site should 
activel y pursue options for returning the stud y inte rvention to the storage conditions 
described in the labeling, as soon as possible. Once an excursion is identified, the 
study  intervention must be quarantined and not used until Pfizer provides permission 
to use the study  intervention. Specific details reg arding the definition of an excursion 
and information the site should report for each excursion will be provided to the site 
in the I P manual.
4.Any storage conditions stated in the SRSD will be superseded by  the storage 
conditions stated on the label.
5.Study interventions should be stored in their original containers.
6.See the IP manual for storage conditions o f the study  intervention once diluted.

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 2020
PFIZER CONFIDENTIAL
Page 657.The investigator, institution, or the head of the medical institution (where applicable) 
is responsible for stud yintervention accountability , reconciliation, and record 
maintenance (ie, receipt, reconciliation, and final disposition records), such as the 
IPAL or sponsor -approved equivalent. All study  interventions will be accounted for 
using a stud y intervention acc ountabilit y form/record. 
8.Further guidance and information for the final disposition of unused study  
interventions are provided in the I P manual. All destruction must be adequately  
documented. If destruction is authorized to take place at the investigator site, the 
investigator must ensure that the materials are destroy ed in compliance with 
applicable environmental regulations, institutional policy , and any  special instructions 
provided b y Pfizer.
Upon identification of a product complaint, notify the spons or within 1 business day  of 
discov
ery as described in the I P Manual.
6.2.1. Preparation and Dispensing
A qualified staff member will dispense the study  intervention in quantities appropriate to the 
dose cohort, participant randomization and according to the SoA.
See the IP manual for instructions on how to prepare the study  intervention for 
administration. Study  intervention should be prepared and dispensed b y an appropriatel y 
qualified and experienced member of the stud y staff (eg, ph ysician,nurse, phy sician’s 
assistant, nurse practitioner, pharmacy  assistant/technician, or pharmacist) as allowed by  
local, state, and institutional guidance.
PF-07304814 and placebo will be prepared by  qualified unblinded site personnel according 
to the I P man
ual.Thestudy  intervention will be administered in a blinded fashion to the
participant s.
6.3. Measures to Minimize Bias: Randomization and Blinding
6.3.1. Allocation to Study Intervention
Allocation of participants to treatment groups will proceed through the us e of an IRT s ystem.
The site personnel (stud y coordinator or specified designee) will be required to enter or select 
information including but not limited to the user’s ID and password, the protocol number, 
and the participant number. The site personnel wi ll then be provided with a treatment 
assignment, randomization number. The IRT s ystem will provide a confirmation report 
containing the pa rticipant number andrandomization number. The confirmation report must 
be stored in the site’s files. 
Study  interven tionwill be administered b y continuous infusion starting on Day  1as
summarized in theSoA.
The study -specific I RT reference manual and I P manual will provide the contact information 
and further details on the use of the IRT s ystem.

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 2020
PFIZER CONFIDENTIAL
Page 66Participants in each cohort will be assigned to receive study  intervention according to 
randomization scheme. Investigators w ill remain blinded to each participant’s assigned study  
intervention throughout the course of the stud y.In order to maintain this blind, an otherwise 
uninvolved thi rd party  will be responsible for the preparation and dispensing of all study  
intervention a
nd will endeavor to ensure that there are no differences in time taken to 
dispens eor visual presentation following randomization .
In the event of a Qualit y Assurance audit, the auditor(s) will be allowed access to unblinded 
study  intervention records at t he site(s) to verify  that randomization/dispensing has been done 
accuratel y.
6.3.2. Breaking the Blind 
The I RT will be programmed with blind-breaking instructions. In case of an emergency , the 
investigator has the sole responsibility  for determining if unblinding of a participant’s 
treatment assignment is warranted. Participant safety  must alway s be the first consideration 
in making such a determination. If the investigator decides that unblinding is warranted, the 
investigator should make every  effort t o contact the sponsor prior to unblinding a 
participant’s treatment assignment unless this could delay  further management of the 
participa nt.If a participant’s treatment assignment is unblinded, the sponsor must be notified 
within 24 hours after breaking the blind. The date and reason that the blind was broken must 
be recorded in the source documentation and CRF.
The study -specific I RT refe rence manual and IP manual will provide the contact information 
and further details on the use of the IRT s ystem.
6.4.Stud y Intervention Compliance
Participants will receive study  intervention directly  from the investigator or designee, under 
medical supervisi on.The date and time of each dose administered in the clinic (start and end 
time) will be recorded in the source docu
ments and recorded in the CRF. The dose of study  
intervention and study  participant identification will be confirmed at the time of dosing bya 
member of the stud y site staff other than the person administering the stud y intervention.
The site will complete the required dosage Preparation Record located in the I P manual. The 
use of the Preparation Record is preferred ,but it does not preclud e the use of an existing 
appropriate clinical site documentation system. The existing clinical site's documentation 
system should capture all pertinent/required information on the preparation and 
administration of the dose. This may  be used in place of the Preparation Record after 
approval from the sponsor and/or designee.
A record of the number of PF-07304814 vials dispe nsed to and the volume of PF -07304814 
or placebo administered to each participant must be maintained and reconciled with study  
interventio n and compliance records. Intervention start and stop timesand date s, including 
times for intervention delay s and/or dose reductions , will also be recorded in the CRF.

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 2020
PFIZER CONFIDENTIAL
Page 676.5. C oncomitant Therapy 
Medications taken prior to dosing will be documented as prior medicat ions. Medications 
taken after the first dose of study  intervention has been adminis tered will be documented as 
concomitant medications. All concomitant medications taken during the study  must be 
recorded in study  records with indication, daily  dose, and start and stop dates of 
administration. Participants will be queried about concomitan t medication (including topical 
medications and treatments, over -the-counter and prescription medications and treatments, 
herbals, and vaccinations) at each visit. Any new concomitant medications or dose changes 
to current concomitant medications should be evaluated for potential new or worsening 
adverse events.
Study  intervention is to be administered on top of SoC for this study .It is recognized that 
S
oC may  change duri ng the course of the study , and it is therefore important to meticulously  
capture all S
oC in the CRF.
Prohibited medications a re shown in Appe ndix 8: Prohibited Medications .
Hormonal therap y for purposes of contracepti on or postmen opausal replacement therap y will 
not be allowed to be used in participants (see Appendix 4: Contraceptive Guidance ).
6.5.1. Rescue Medic ine
There is no rescue therapy to reverse the AEs observed with PF-07304814; standard medical 
support ivecare must be provided to manage the AEs.
6.6.Dose Modification
Planned nominal doses are projected based on nonclinical data and may  be modified based 
on emerging safety , tolerability , and PK data.
6.6.1.
Dose Escalation and Stopping Rules 
Dosing of an y individu al participant may  be stopped at any  time if it is the Investigator’s 
opinion that the risks outweigh an y potential benefit, based on the available individual 
subject safet y data . If possible, the Investigator should contact the Spons or to discuss before 
discontinuation .For participants in Part 2progression of COVID -19 disease should not 
automatically  lead to stopping dosing, but the Investigator should consider the overall risk 
benefit. Precautionary  sentinel dosing will be used in each dose -escalating c ohort in Part1.
A small cohort of 2 participants (1 receiving PF- 07304814 and 1 receiving placebo) will be 
dosed prior to the remainder of the cohort. All available safet y and tolerability  data from the 
2 sentinel participants up to at least Day 3 at 24 hour s post completion of dosing will be 
reviewed b y the Investigator(s) (if available) , the study  team and IRC.The independent IRC 
will then determine whether it is safe to proceed to dose the remaining participants in the 
cohort. 

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 2020
PFIZER CONFIDENTIAL
Page 68During the SAD ( Part 1 ) of the study , emerging safet y, tolerability, and PK data will be 
reviewed b y the Investigator(s) (if available) , the study  team and IRC.The independent IRC 
will then determine whether it is safe to proceed to the next dose level .
The decision to escalate will be based on a minimum of preliminary  PK data through 
24hours (Day  2), available safet y and tolerability data through Day  6,and all reported SAEs 
through to 
Day 9in at least 6participants. In addition, the Investigator(s) (if available) , the 
study  team and the IRC will review available safety  and tolerability  data up to Day  3 and all 
reported SAEs up to Day 6 in the remaining 2participants, along with cumul ative safet y and 
PK data from prior dose levels.
Progression to Pa rt 2: MAD will occur if sa fety, tolerability , and PK data from the prior 
Part 1: SAD 24h infusion cohorts are determined to be supportive and acceptable by  a 
competent regulatory  authority .
During the M AD ( Part 2) of the stud y, emerging safet y, tolerability, and PK data will be 
reviewed by the Investigator(s) (if available) and the study  team . Competent authorities will 
be consulted before proceed ingto the next higher dose cohort . The decis ion to escalate will 
be based on a minimum of preliminary  PK data through 120h (end of infusion) , available 
safet y and tolerability data through Day 7, and all reported SAEs through to Day 10in at 
least 
6participants. In addition, the Investigator(s) (if available) andthe study  team will 
review available safety and tolerability in the remaining 2participants, along with cumulative 
safet y and PK data from prior dose levels.
Dose escalation stopping rules will be used to determine whet her the maximal tolerated dose 
has been attained. Dose escalation may  be stopped if it is determined that the limits of safety 
and/or tolerability have been reached. If dose escalation is stopped because of an y of these 
criteria, additional cohort (s)may receive the same or lower doses of the investigational 
product .
The dose escalation will be terminated based on t he following criteria:
If 50% or more of the participants receiving active drug at a given dose level (but not 
participants receiving placebo) d evelop similar clinically  significant laboratory , ECG, 
or vital sign abnormalities , considered to be drug -relate d, in the same organ class, and 
indicating dose -limiting intolerance .
Severe nonserious AEs, considered as, at least, possibly  related to investigational 
product administration, in 2 participants at a given dose level (but not participants 
receiving place bo), independent of within or not within the same sy stem organ class, 
indicating dose -limiting intolerance .
In the event of an SAE in a particip ant receiving active treatment, causality must be 
fully  assessed by  the investigator and sponsor. If it is deeme d to be not drug related, 
dosing may  continue. 
If it is deemed to be drug related or unknown b y either the 
investigator or sponsor, dosing will be paused and the SAE will be evaluated by  the 

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 2020
PFIZER CONFIDENTIAL
Page 706.7.Intervention A fter the End of the Study
No intervention will be provided to study  participants after the end of the study .
7.DISCONTINUATION OF S TUDY INTERVENTION AN D PARTICIPANT 
DISCONTINUATION/WITH DRAWAL
7.1.Discontinuation of Study Interventio n
In rare instances, it may  be necessary  for a participant to permanentl y discontinue study  
intervention (definitive discontinuation) .Reasons for definitive discontinuation of study  
intervention include (but are not limited to) the following : AEs , Phy sicia
ndecision, 
withdrawal b y participants .
Note that discontinuation of study  intervention does not represent withdrawal from the stud y.
If study  intervention is definitively  discontinued, the participant will remain in the study  to 
be evaluated for safet y and other assessments. See the SoA for data to be collected at the time 
of discontinuation of study  intervention and follow -up for any  further evaluations that need 
to be completed.
In the event of discontinuation of study  interventi on,it must be documented on the 
appropriate CRF/in the medical records whether the participant is discontinuing further 
receipt of stud y intervention or also from study  procedures, posttreatment study  follow -
up, 
and/or future collection of addition al infor mation.
At the discretion of the Investigator, in the event of a significant safet y concern such as 
changes in renal or cardiac function , infusion of the study  intervention may be interrupted or 
terminated.
If anaph ylaxis or a serious allergic rea ction is noted, the study  intervention should be 
immediately  stopped, and the participant should be discontinued. Additionally , other adverse 
events or confirmed laboratory  abnormalities judged by  the investigator to be a significant 
safet y concern should 
also le ad to immediate stop to study  intervention .
The Sponsor, in consultation with the independent IRC and/or a competent regulatory  
agency , may  also mandate discontinuation based on review of PK or safety  data.
If a participant discontinues study  inter vention ,
he/she should complete the “Early 
Termination ”visit (SoA).
In addition, intervention will be discontinued for the following changes in ECG.
ECG Changes
A participant who meets either bulleted criteria based on the average of tripl icate ECG 
readings that are deemed to be related to the administration of PF -07304814 will be 
withdrawn from the study intervention .

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 2020
PFIZER CONFIDENTIAL
Page 71QTcF >500 ms ec.
Change from baseline: QTc F>60 ms ec .
If a clinically  significant finding is identified (including, but not limited to ,changes from 
baseline in QT cFafter enrolment ), the investigator or qualified designee will determine if the 
participant can continue in the study  and if any  change in participant management is needed.
This review of the ECG printed at the tim e
of collection must be documented. Any new 
clinically  relevant finding should be reported as an AE.
7.1.1.
Temporary Discontinuation
In Part 1: SAD , if infusion is temporary  interrupted, it should be resumed as soon as possible 
and the complete dose should be a dministered. Temporary  discontinuation for longer than 
2
hours is not permitted. Participants may  temporarily  discontinue from Pa rt 2: MAD for up 
to 6hours over the 120-h infusion period ( ifpossible, each interruption should be no longer 
than 2 hours )toreduce risk to the participant at the discretion of the investigator. If study  
intervention administration is restarted the remaining course will be given. Temporary  
discontinuation for longer than 6 hours is not permitted.
7.1.2. Rechallenge
Not applicable .
7.2.Participant Discontinuation/ Withdrawal F rom the Study
A participant may  withdraw from the study  at an y time at his/her own request. Reasons for 
discontinuation from the study  include the following:
Refused further follow -up;
Lost to follow -up;
Death ;
Physician
decision ;
Pregnancy ;
Study  terminated by  sponsor .
At the time of discontinuing from the stud y, if possible, an earl y discontinuation visit should 
be conducted .See theSoA for assessments to be collected at the time of study  
discontinuation and follow -up and for an y further evaluations that need to be completed. 
The early  discontinuation visit applies only  to participants who ar e enrolled/ randomized and 
then are prematurely  withdrawn from the study .Participants should be question
ed regarding 
their reason for withdrawal.

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 2020
PFIZER CONFIDENTIAL
Page 72The participant will be permanentl y discontinued both from the study intervention and from 
the study  at that time.
If a participant withdraws from the study , he/she may  request destruction of any  remaining 
samples taken and not tested ,andthe investigator must document any  such requests in the 
site study  records and notify  the sponsor accordingly .
If the partici pant withdraws from the study  and also withdraws consent (see Section 7.2.1) 
for disclosure of future information, no further evaluations should be performed and no 
additional data should be collected. The sponsor may  retain and continue to use any  data 
collected befo re such withdrawal of consent
.
Lack of completion of all or an y of the withdrawal/earl y termination procedures will not be 
viewed as protocol deviations so long as the participant ’s safet y was preserved.
7.2.1. Withdrawal of Consent
Participant s who request to di scontinue receipt of study  inter ve ntion will remain in the study  
and must continue to be followed for protocol -specified follow -up procedures. The onl y 
exception to this is when a participant specificall y withdraws consent for any further contact 
with him or her or persons previously au thorized by  the participant to provide this 
information. Participant s should notify  the investigator in writing of the decision to withdraw 
consent from future follow -up, whenever possible. The withdrawal of consent should be
explained in detail in the medi cal records b y the investigator, as to whether the withdrawal is 
only from further receipt of study  intervention or also from study  procedures and/or 
posttreatment study  follow -up and entered on the appropriate CRF page. In the event that 
vital status (whe ther the participant is alive or dead) is being measured, publicly  available 
information should be used to determine vital status only  as appropriatel y directed in 
accordance with local law.
7.3.Lost to Fol low-up 
A par ticipant will be considered lost to foll ow-up if he or she repeatedl y fails to return for 
scheduled visits and is unable to be contacted b y the study  site.
The following actions must be taken if a participant fails to attend a required study  visit:
The sit e must attempt to contact the participan
t and reschedule the missed visit as 
soon as possible and counsel the participant on the importance of maintaining the 
assigned visit schedule and ascertain whether or not the participant wishes to and/or 
should cont inue in the study ;
Before a participant is deemed lost to follow -up, the investigator or designee must 
make every  effort to regain contact with the participant (where possible, 3 telephone 
calls and, if necessary , a certified letter to the participant’s la st known mailing 
address or local equiva lent methods). These contact attempts should be documented 
in the participant’s medical record ;

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 2020
PFIZER CONFIDENTIAL
Page 73Should the participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study.
8.STUDY ASS ESSMENTS AND PROCEDU RES
The investigator (or an appropriate delegate at the investigator site) must obtain a signed and 
dated ICD before performing any  study -specific procedures.
Study  procedures and their timing are summarized in the SoA.Protocol waivers or 
exemptions a re not allowed.
Safety  issues should be discussed with the sponsor immediately  upon occurrence or 
awareness to determine whether the participant should continue or discontinue study  
intervention.
Adherence to the stud y design requirements, including those s
pecified in the SoA, is essential 
and required for stud y conduct.
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eli gibility  criteria. The investigator will maintain a scree ning log to 
record details of all participants screened and to confirm eligibility  or record reasons for 
screening failure, as applicable.
Procedures conducted as part of the participant’s routine clinical management (eg, blood 
count) and obtained before s igning of the IC Dmay be utilized for screening purposes 
provided the procedures met the protocol -specified criteria and were performed within the 
time frame defined in the SoA.
Every  effort should be made to ensure that protocol -required tests and procedures are 
completed as described. However, it is anticipated that from time to time there may  be 
circumstances outside the control of the investigator that may  make it unfeasible to perform 
the test. I n these cases, the investigator m usttake all steps necessary  to ensure the safet y and 
well-being of the participant
.When a protocol -required test cannot be performed, the 
investigator will document the reason for the missed test an d any corrective and preventive 
actions that he or she h as taken to ensure that required processes are adhered to as soon as 
possible. The study  team must be informed of these incidents in a timely  manner.
For samples being collected and shipped, detailed collection, processing, storage, and 
shipment instructions and contact information will be provided to the investigator site prior 
to initiation of the study as outlined in the lab manual.
The total blood sampling volume for individual participant s in this study  is approximately  
225 mL in Part 1: SAD and 3 60mL inPart2: MAD .The actual collection times of blood 
sampling may  change. Additional blood samples may  be taken for safet y assessments at 
times specified b y Pfizer, provided the total volume taken during the stud y does not exceed 
550mL during an y perio d of 60consecutive day s.

PF-07304814
Protocol C4611001Final Protocol Amendment 4, 15 December 2020
PFIZER CONFIDENTIAL
Page 74Note : In order to draw blood samples for safety assessments, pharmacokinetics, 
 a central line or midline is notrequired by the 
study protocol, and should only be placed if clinically warranted; 
•During dosing of the interventional product, the blood draws for pharmacokinetics 
should be done using the contralateral arm to the one being used for infusion of the study intervention. (When a simultaneous blood sample is required for safety assessments,  it is recommended to use the same venipuncture).
8.1. Efficacy Assessments
Not applicable.
8.2. Safety Assessments
Planned time points for all safety assessments are provided in the SoA. Unscheduled clinical 
laboratory measurements may be obtained at  any time during the study to assess any 
perceived safety issues.
8.2.1. Physical Examinations
A complete physical examination will include, at a minimum, assessments of the 
cardiovascular, respiratory, gastrointestinal, and neurological systems. Height and weight will also be measured and recorded (height may be reported by participant if necessary) at screening only.
A targeted physical examination will include, at a minimum, assessments of the skin, lungs, 
cardiovascular system, and abdomen (liver and spleen).
Investigators should pay special attention to clinical signs related to previous serious 
illnesses.
8.2.2. Vital Signs
Temperature (Oral, Tympanic, Axillary or Tem poral), pulse rate, respiratory rate, pulse 
oximetry/SpO
2, and blood pressure will be assessed. It is preferred that body temperature be 
collected using the same method for the same participant throughout the study.
Blood pressure and pulse rate measurements will be assessed in the supine position
preferably with a completely automated device. Manual techniques will be used only if an automated device is not available.
Blood pressure and pulse rate measurements should be preceded by at least 5 minutes of rest 
for the participant in a quiet setting without distractions (eg, television, cell phones). Vital signs (to be taken before blood collection for laboratory tests) will include 1 pulse rate and 1 blood pressure measurements.CCI
CCI
PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 2020
PFIZER CONFIDENTIAL
Page 758.2.3. Electrocardiograms
Triplicate standard 12-l ead ECGs utilizing limb leads(with a 10 second rhy thm strip) should 
be collected at times (except for single measurement at screening) specified in the SoA
section of this protocol using an ECG machine that automatically  calculates the heart rate and 
meas ures PR, RR, QT, and QTc intervals and QRS complex .Alternative lead placement 
methodology  using torso leads (eg ,Mason -Likar) is not recommended given the potential 
risk of discrepancies with ECGs acquired using standard limb lead placement. All scheduled
ECGsshould be performed after the participant has rested quietly  for at least 10 minutes in a 
supine position and taken before blood collection for labora tory tests. 
Once started, t riplicate 12 -lead ECGs will be completed within 20 minutes of start of the 1st 
reading; the triplicate ECG measurements collected before dose administration on Day 1 will 
serve as each participant’s baseline QTc value. 
If a) a post-dose QTc interval remains ≥60 msecfrom the baseline andis >450 msec; or 
b)an absolute QTc value is ≥500 msecfor an y scheduled ECG for greater than 4 hours (or 
sooner, at the discretion of the investigator) ;or c) QTc intervals get progressively  longer, the 
participant should undergo continuous ECG monitoring. A cardiologist should be consulted 
if QTc interval s do not return to less than the criterion listed above after 8 hours of 
monitoring (or sooner, at the discretion of the investigator).
ECG data may  be locally read for dos e escalation purpose and then will be submitted to a 
central laboratory  for measurement and final CSR reporting . The final ECG report from the 
central laboratory  should be maintained in the participant’s source documentation and be the 
final interpretation of the ECG recording. Any clinically  significant changes from the 
baseline/Day  1 ECG may potentially  be AEs ( Appendix 7: ECG Findings of Potential 
Clinical Concern ) and should be evaluated further, as clinically  warranted. 
In som e cases, it may  be appropriate to repeat abnormal ECGs to rule out improper lead 
placement as contributing to the ECG abnormality. It is important that leads 
beplaced in the
same positions each time in order to achieve precise ECG recordings. If a machine -read QTc 
value is prolonged, as defined above, repeat measurements may  not be necessary  if a 
qualified medical provider’s interpretation determines that the QTc values are i n the 
acceptable range.
ECG values of potential clinical concern arelisted in Appendix 7: ECG Findings of Potential 
Clinical Concern .
8.2.3.1. Continuous Cardiac Monitoring by Telemetry
All abnormal rh ythms will be recorded and reviewed by  the study  physician for the presence 
of rh ythms of potential clinical concern. The time, duration, and description of the clinicall y 
significant event will be recorded in the CRF. In addition, a printed record of the tracing(s) of 
the clinically  significant rhy thm(s) will be made and retained with other source documents.

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 2020
PFIZER CONFIDENTIAL
Page 76Telemetry  should be collected using a centralized sy stem to monitor and preserve important 
events for future evaluat ions. Holter monitoring should not be used in parallel with 
continuous telemetry, unless it is the only  means of data storage available at the investigato r 
site, or verifiable arrh ythmia quantification is required. To establish a baseline, telemetry  
should be recorded for at least 2 hours on Day  -1 or before dosing on Day  1 of each cohort in 
Part 1 : SAD .This may  be done immediatel y prior to dosing or at so me 2
-hour continuous 
interval in the 24 hours prior to dosing, as long as the recording is performed w hen the 
participant is awake. Telemetry  may  be stopped within a reasonabl y short period of time 
prior to dosing, in order to avoid interference with study operations conducted immediately  
before dosing. However, it is expected that the telemetry  leads will be in place and the 
system connected prior to dosing.
8.2.4. Clinical Safety Laboratory Assessments
See Appendix 2 for the list of clinical safet y laboratory  tests to be performed and the SoA for 
the timing and frequency. All protocol -required laboratory  assessments, as defined in 
Appendix 2: Clinical L aboratory  Tests , must be conducte d in accordance with the laboratory  
manual and the SoA. Unscheduled clinical laboratory  measurements may  be obtained at an y 
time during the stud y to ass ess an y perceived safety  issues.
The investigator must review the laboratory  report, document this review, and record any  
clinically  relevant changes occurring during the study
 in the AE section of the CRF.
Clinically  significant abnormal laboratory  findings are those which are not associated with 
the underl ying disease, unless judge d by the investigator to be more severe than expected for 
the participant's condition.
All laboratory  tests with values considered clinically  significantl y abnormal during 
participation in the study  or within 28 calendar days after the last dose of study  intervention 
should be repeated until the values return to normal or baseline or are no longer considered 
clinically  significant b y the investigator or medical monitor.
If such values do not return to normal/baseline within a period of time judged reasonable b y 
the investigator, the etiology  should be identified and the sponsor notified.
See Appendix 6 for suggested actions and follow -up asse ssments in the event of potential 
drug-induced liver injury.
8.2.5. Pregnancy Testing
Pregnancy  tests may  be urine or serum tests but must have a sensitivity  of at least 
25mIU/mL. Pregnancy  tests will be performed in WOCBP at the times listed in the SoA .
Pregnancy tests will also be done whenever 1 menstrual cy cle is missed during the active 
treatment period (or when potential pregnancy  is otherwise suspected) and post treatment if 
this is an in -clinic visit .Pregnancy tests may also be repeated if requested by  IRBs/ECs or if 
required b y local regulations. If a urine test cannot be confirmed as negative (eg, an 
ambiguous result), a serum pregnancy  test is requi red.In such cases, the participant must be 
excluded if the serum pregnancy  result is positive .

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 2020
PFIZER CONFIDENTIAL
Page 778.3. Adverse Events and Serious Adverse Events
The definitions of an AE and an SAE can be found in Section 10.3.
AEswill be reported b y the participant (or, when appropriate, b y a caregiver, surrogate, or 
the participant's legall y authorized representative).
Theinvestigator and an y qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible to pursue 
and obtain adequate information both to determine the outcome and to ass esswhether the 
event meets the criteria for classification as an SAE or caused the participant to discontinue 
the study  intervention (see Section 7.1).
Each participant will be questioned about the occurrence of AEs in a nonleading manner.
In addition, the investigator may  be requested by  Pfizer Safet y to obtain specific follow -
up 
information in an expedited fashion.
8.3.1. Time Period and Fr equency for C ollecting AE and SAE Information
The time period for actively  eliciting and collecting AEs and SAEs (“active collection 
period”) for each participant begins from the time the participant provides informed consent, 
which is obtained before the participant ’s participation in the study  (ie, before undergoing 
any study -related procedure and/or receiving study  intervention ), through and including a 
minimum of 28 calendar day s, except as indicated below, after the last administration of the 
study  intervention.
Follow -up by  the investigator continues throughout and after the active collection period and 
until the AE or SAE or its sequelae resolve or stabilize at a level acceptable to the 
investigator and Pfizer concurs with that assessment.
For participants who are screen failures, the active collection period ends when screen failure 
status is determined.
If the participan t withdraws from the study  and also withdraws consent for the collection of 
future information, the active collection period ends when consent is withdrawn.
If a participant definitively  discontinues or temporarily  discontinues study  intervention 
because o fan AE or SAE, the AE or SAE must be recorded on the CRF and the SAE 
reported using the CT SAE Report Form.
Investigators are not obligated to activel y seek AE sor SAE safter the participant has 
concluded study  participation .However, if the investigator learns of any  SAE, including a 
death, at an y time after a participant has completed the study , and he/she considers the event 
to be reasonably  related to the study  intervention, the investigator m ust promptly  report the 
SAE to Pfizer using the CT SAE Repor t Form .

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 2020
PFIZER CONFIDENTIAL
Page 788.3.1.1. Reporting SAEs to Pfizer Safety
All SAEs occurring in a participant during the active collection period as described in 
Section 8.3.1 are reported to Pfizer Safety  on the CT SAE Report Form i mmediately  upon 
awareness and under no circumstance should this exceed 24 hours, as indicated in 
Section 10.3 .The investigator wil l submit any  updated SAE data to the sponsor within 
24 hours of it being available.
8.3.1.2. Recording Nonserious AEs and SAEs on the CRF
All nonserious AEs and SAEs occurring in a participant during the active collection period , 
which begins after obtaining informed consent as described in Section 8.3.1 , will be recorded 
on the AE section of the CRF.
The investigator is to record on the CRF all directly  observed and all spontaneously  reported 
AEs and SAEs reported by  the participant.
8.3.2. Method of Detecting AEs and SAEs
The method of recording, evaluating, and assessing causality  of AE sand SAE sand the 
procedures for completing and transmitting SAE reports are provided in Section 10.3.
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and 
nonleading verbal questioning of the participant is the preferred method to inquire about 
AEoccurrences.
8.3.3. Follow -up of AEs and SA Es
After the initial AE/SAE report, the investigator is required to proactivel y follow each 
participant at subsequent visits/contacts. For each event, the investigator must pursue and 
obtain adequate information until resolution, stabilization, the event i s othe rwise explained, 
or the participant is lost to follow
-up (as defined in Section 7.3).
In general, follow -
up information will include a description of the event in sufficient detail to 
allow for a complete medical assessment of the case and independent determination of 
possibl e causality . Any information relevant to the event, such as concomitant medications 
and illnesses, must be provided. In the case of a participant death, a summary  of ava ilable 
autopsy  findings must be submitted as soon as possible to Pfizer Safety . 
Furthe r information on follow -up procedures is given in Section 10.3.
8.3.4.
Regulatory Reporting Requirements for SAEs
Prompt notification by  the investigator to the sponsor of a n SAE is essential so that legal 
obligations and ethical responsibilities towards the safet y of participants and the safet y of a 
study  intervention under clinical investigation are met.

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 2020
PFIZER CONFIDENTIAL
Page 79The sponsor has a legal responsibility  to notify  both the local regulatory  authority  and other 
regulatory  agencies about the safet y of a stud y intervention under clinical investigation. The 
sponsor will comply  with country -specific regulatory  requirements relating to safet y
reporting to the regulatory  authorit y, IRBs/ECs, and investigators.
Investigator safety  reports must be prepared for SUSAR saccording to local regulatory  
requirements and sponsor policy  and forwarded to investigators as necessary .
An investigator who rece ives SUSAR sor other specific safety information (eg, summary or 
listing of SAEs) from the sponsor will review and then file it along with the SRSD (s) for the 
study and will notify  the IRB/EC, if appropriate according to local requirements.
8.3.5. Exposure During Pregnancy or Breastfeeding, and Occupational Exposure
Exposure to the study  interventio nunder stud y during pregnancy  or breastfeeding and 
occupational exposure are reportable to Pfizer Safety  within 24 hours of investigator 
awareness.
8.3.5.1. Exposure Duri ng Pregnancy
An EDP occurs if: 
A female participant is found to be pregnant while receiving or after discontinuing 
study  intervention .
A male participant who is receiving or has discontinued study  intervention exposes a 
female partner prior to or around the time of conception .
A female is found to be pregnant while being exposed or having been exposed to 
study  intervention due to environmental exposure. Below are examples of 
environmental exposure during pregnancy :
A female family  member or healthcare provider reports that she is pregnant after 
having been exposed to the study  intervention by ingestion or skin contact .
A male famil y member or healthcare provider who has been exposed to the study  
intervention by  ingestion or skin contact then exposes his fe male partner prior to 
or around the time of conception.
The investigator must report EDP to Pfizer Safety within 24 hours of the investigator’s 
awareness, irrespective of whether an SAE has occurred. The initial information submitted 
should include the an ticipated date of delivery  (see below for information related to 
termination of pregnancy).

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 2020
PFIZER CONFIDENTIAL
Page 80If EDP occurs in a participant or a participant’s partner, the investigator must report 
this information to Pfizer Safety on the CT SAE Report Form and an EDP 
Suppl emental Form, regardless of whether an SAE has occurred. Details of the 
pregnancy  will be collected after the start of study  intervention and until 28 day s after 
the last dose.
If EDP occurs in the setting of environmental exposure, the investigator must r eport 
information to Pfizer Safety  using the CT SAE Report Form and EDP Supplemental 
Form. Since the exposure information does not pertain to the participant enrolled in 
the study , the information is not recorded on a CRF; however, a copy  of the 
completed CT SAE Report Form is maintained in the investigator site file.
Follow -up is conducted to obtain general information on the pregnancy  and its outcome for 
all EDP reports with an unknown outcome. The investigator will follow the pregnancy  until 
completion ( or until pregnancy  termination) and notify  Pfizer Safet y of the outcome as a 
follow -up to the initial EDP S upplemental Form. In the case of a live birth, the structural 
integrit y of the neonate can be assessed at the time of birth. In the event o f a termin ation, the 
reason(s) for termination should be specified and, if clinically  possible, the structural 
integrit y of the terminated fetus should be assessed by gross visual inspection (unless 
pre-procedure test findings are conclusive for a congenit al anomal yand the findings are 
reported).
Abnormal pregnancy  outcomes are considered SAEs. If the outcome of the pregnancy meets 
the criteria for an SAE (ie, ectopic pregnancy , spontaneous abortion, intrauterine fetal 
demise, neonatal death, or congenital anomal y in a live -born bab y, a terminated fetus, an 
intrauterine fetal demise, or a neonatal death), the investigator should follow the procedures 
for reporting SAEs. Additional information about pregnancy  outcomes that are reported to 
Pfizer Safety  as SA Es follows: 
Spontaneous abortion includ ingmiscarriage and missed abortion.
Neonatal deaths that occur within 1 month of birth should be reported, without regard 
to causality , as SAEs. In addition, infant deaths after 1 month should be reported as 
SAEs when the inv
estigator assesses the infant death as related or possibly  related to 
exposure to the study  intervention. 
Additional information regarding the EDP may  be requested by  the sponsor. Further 
follow -up of birth outcomes will be handled on a case- by-case basis (eg, follow -up on 
preterm infants to identify developmental delay s).In the case of paternal exposure, the 
investigator will provide the participant with the Pregnant Partner Release of Information 
Form to deliver to his partner. The investigator must doc ument in the source documents that 
the participant was given the Pregnant Partner Release of Information Form to provide to his 
partner.

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 2020
PFIZER CONFIDENTIAL
Page 818.3.5.2. Exposure During Breastfeeding
An exposure during breastfeeding occurs if: 
A female participant is found to be breastfeeding while receiving or after 
discontinuing study  intervention .
A female is found to be breastfeeding while being exposed or having been exposed to 
study  intervention (ie, env ironmental exposure). An example of environmental 
exposure during breastfeeding is a female family  member or healthcare provider who 
reports that she is breastfeeding after having been exposed to the study  intervention 
by inhalation or skin contact.
The i nvestigator must report exposure during breastfeeding to Pfizer Safety  within 24 hours 
of the investigator’s awareness, irrespective of whether an SAE has occurred. The 
information must be reported using the CT SAE Report Form. When exposure during 
breastf eeding occurs in the setting of environmental exposure, the exposure information does 
not pertain to the participant enrolled in the study , so the information is not recorded on a 
CRF. However, a cop y of the completed CT SAE Report Form is maintained in th e 
investigator site file.
An exposure during breastfeeding report is not created when a Pfizer drug specificall y 
approved for use in breastfeeding women (eg, vitamins) is administered in accord with 
authorized use. However, if the infant experiences an SAE associated with such a drug, the 
SAE is reported together with the exposure dur ing breastfeeding.
8.3.5.3. Occupational Exposure
An occupational exposure occurs when a person receives unplanned direct contact with the 
study  intervention , which ma y or may  not lead to the occurrence of an AE. Such persons may  
include healthcare providers , famil y members, and other roles that are involved in the trial 
participant’s care.
The investigator must report occupational exposure to Pfizer Safet y within 24 hours of the 
investigator’s awareness, regardless of whether there is an associated SAE. The informa tion 
must be reported using the CT SAE Report Form. Since the information does not pertain to a 
participant enrolled in the study , the information is not recorded on a CRF; however, a copy  
of the completed CT SAE Report Form is maintained in the investigat or site file .
8.3.6.
Cardiovascular and Death Events
Not applicable . 
8.3.7. Disease Related Events and/or Diseas eRelated Outcomes Not Qualifying as AEs 
or SAEs
Not applic able.

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 2020
PFIZER CONFIDENTIAL
Page 828.3.8. Adverse Events of Special Interest
Not applicable .
8.3.8.1. Lack of Efficacy
Not applicable.
8.3.9. Medical Device Deficiencies
Not applicable .
8.3.10. Medication Errors
Medication errors may  result from the administration of the study  intervention to the wrong 
participant , or at the wrong time, or at the wrong dose.
Exposures to the study  intervention under stud y may occur in clinical trial settings, such as 
medication er rors.
Safety Event Recorded on the CRF Reported on the CT SAE Report Form  to 
Pfizer Safety Within 24 Hours of Awareness
Medication errors All (regardless of whether 
associated with an AE)Only if ass ociated with an SAE
Medication errors include:
Medication errors involving participant exposure to the study  intervention .
Potential medication errors or uses outside of what is foreseen in the protocol that do 
or do not involve the study participant .
Such medication errors occurring to a stud y partici pant are to be captured on the medication 
error page of the CRF, which is a specific version of the AE page.
In the event of a medication dosing error, the sponsor should be notified within 24 hours .
Whether ornot the medication error is accompanied by  an AE, as determined by  the 
investigator, the medication error is recorded on the medication error page of the CRF and, if 
applicable, an y associated AE(s), serious and nonserious, are recorded on theAE page of the 
CRF.
Medication errors should be reported to Pfizer Safety within 24 hours on a CT SAE Report 
Form only when associated with an SAE.
8.4.Treatment of Overdose
For this study , any  dose of 
PF-07304814 greater than twice the intended dose within a 
24-hour ti me period (±2 hours ) will be considered an overdose.

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 2020
PFIZER CONFIDENTIAL
Page 83Sponsor does not recommend specific treatment for an overdose.
In the event of an overdose, the investigator should:
1.Contact the medical m onitor within 24 hours .
2.Closely  monitor the participant for an y AEs/SAE sand laboratory  abnormalities for at 
least 5 half -lives or 28 calendar day s after the overdose of PF-07304814 (whichever is 
longer) .Closely  monitor the particip ant for an y AEs/SAEs .
3.Document the quantit y of the excess dose as well as the duration of the overdose in the 
CRF.
4.Overdose is reportable to Safety  only when associated with a nSAE .
5.Obtain a blood sample for PK anal ysis within 1 day from the date of the last dose of 
study  intervention if requested by  the medical monitor (determined on a ca se-by-case 
basis).
Decisions regarding dose interruptions or modifications will be made by  the investigator in 
consultation with the 
medical m onitor based on the clinical evaluation of the participant.
8.5.Pharmacokinetics
8.5.1. Plasma for Analysis of PF -07304814 an d PF -00835231
Blood samples of approximately  4mL, to provide a minimum of 1.5mLplasma , will be 
collected into appropriately  labeled tubes containing K 3EDTA for measurement of plasma 
concentrations of PF-07304814 and PF -00835231 as specified in the SoA.Instructions for 
the collection and handling of biological samples will be provided in the lab oratory manual 
or by  the sponsor. The actual date and time (24- hour clock time) of each sample will be 
recorded.
The actual times may chan ge, but the number of samples will remain the same. All efforts 
will be made to obtain the samples at the exact nominal time relative to dosing. Collection of
samples up to and including 12hours after dose administration that are obtained within 
10% of th
e nominal time relative to dosing (eg, within 6 minutes of a 60 -minute sample) will 
not be captured as a protocol deviation, as long as the exact time of the collection is noted on 
the source document and theCRF .Collection of samples more than 10 hours after dose
administration that are obtained ≤1hour away  from the nominal time relative to dosing will 
not be captured as a protocol deviation, as long as the exact time of the collection is noted on 
the source docu ment and the CRF. 

PF-07304814
Protocol C4611001Final Protocol Amendment 4, 15 December 2020
PFIZER CONFIDENTIAL
Page 888.8.5. Specified Protein Research
Approximately 10 mL blood will be collected for plasma PD biomarkers and 10 mL blood 
will be collected for serum PD biomarkers from participants per the SoA. Assessments may 
include biomarker endpoints outlined below. In addition, transporter analysis may be conducted. These data will be used for internal exploratory purposes and will not be included in the CSR. Collection, storage and shipping instructions will be in accordance with the laboratory manual.
8.8.5.1. Plasma PD Biomarker Assessments
Plasma samples will be used to assess cytokines of inflammatory response (eg, IL-1B, IL-2, 
IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13 TNF- α, and IFN- γ) and proteomics. Plasma samples 
will be collected to assess coagulation markers (eg, PT, aPTT, and D-dimer) and fibrinogenat time points described in the SoA.
Residuals of all samples may be banked for up to 5 years for future research. Collection, 
storage and shipping instructions will be in accordance with the laboratory manual.
8.8.5.2. Serum PD Biomarker Assessments
Serum samples will be used to assess biomarkers of generalized endothelial damage/anemia 
(eg, ferritin), cardiac dysfunction (eg, CK, proBNPII, and troponin), haptoglobin, and general markers of sepsis/organ damage (eg, LDH, hsCRP, and cystatin-C), and procalcitonin. In addition, host innate responses will be monitored using serological endpoints (anti-SARS CoV-2). Residuals of all samples may be banked for up to 5 years for future research.Collection, storage and shipping instructions will be in accordance with the laboratory manual.
8.9. Immunogenicity Assessments
Immunogenicity assessments are not included in this study.
8.10. Health Economics
Health economics/medical resource utilization and health economics parameters are not 
evaluated in this study.
9. STATISTICAL CONSIDERATIONS
Detailed methodology for summary and statistical analyses of the data collected in this study 
is outlined here and further detailed in the SAP, which will be maintained by the sponsor.The SAP may modify what is outlined in the protocol where appropriate; however, any major modifications of the primary endpoint definitions or their analyses will also be reflected in a protocol amendment.CCI
PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 2020
PFIZER CONFIDENTIAL
Page 899.1.Estimands and Statistical Hypotheses
There are no estimands or statistical hy potheses for this study .
9.2.Sample Size Determination
No formal sample size calculation was performed.
The sample size for both Part 1: SAD and Part 2: MAD of approximately 8 participants per 
cohort (6 PF -07304814:2 placebo) has been chosen based on the need to minimize first 
exposure to humans of a new chemical entity  and the requirements to provide adequate safet y 
and toleration information at each dose level.
Participants who discontinue forreasons other than drug-related safety  events during the trial 
may be replaced at the discretion of the Sponsor and I nvestigator.
9.3.Analysis Sets
For purposes of analy sis, the following anal ysis sets are defined:
Population Description
Enrolled /Randomly  
assigned to stud y 
intervention"Enrolled" means a participant's, or his/her lega lly authorized
representative’s, agreement to participate in a clinical study  
following completion of the informed consent process.
Potential participants who are screened for the purpose of 
determining eligibility  for the study , but do not participate in 
the study , are not considered enrolled, unless otherwise 
specified b y the protocol.
Evaluable All participants randomly  assign ed to study  intervention and 
who take at least 1dose of study  intervention .
Safety All participants randomly  assigned to study  intervention and 
who take at least 1 dose of study  intervention .Participants 
will be anal yzed according to the 
product they actually  
received.
PK Concentration Set All participants randomly  assigned to study intervention and 
who take at least 1 dose of s tudy intervention and in whom at 
least 1 concentration value is reported for the given part of 
the study  (Part 1: SAD or Part 2: MAD ).
PK Parameter Set All participants randomly  assigned to study intervention and 
who take at least 1 dose of study interven tion and in whom at 
least 1 of the PK parameters of interest are reported for the 
given part of the stud y (Part 1 : SAD or Part 2: MAD ).

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 2020
PFIZER CONFIDENTIAL
Page 90Population Description
Biomarker Anal ysis Set All participants randomly  assigned to study  intervention and 
who take at least 1 dose of study  intervention and in whom at 
least 1 of the biomarkers of interest are reported for the given 
part of the stud y (Part 1: SAD or Part 2: MAD ).
9.4. Statistical Analyses
The SAP will be developed and finalized before any anal yses are pe rformed and will 
describe the anal yses and procedures for accounting for missing, unused, and spurious data.
This section is a summary of the planned statistical analy ses of the primary  and secondary  
endpoints.
9.4.1. Primary Endpoint : Safety
All safet y anal yses will be performed on the saf ety population. No formal analy ses are 
planned for safet y data.
AEs, ECGs, BP, pulse rate, pulse oximetry /SpO 2, clinical laboratory  data and infusion site 
reactions will be reviewed and summarized on an ongoing basis during the study  to evaluate 
the safet yof participants. Any clinical laboratory , ECG, BP, and pulse rate abnormalities of 
potential clinical concern will be described. Safet y data will be presented in tabular and/or 
graphical format and summarized descriptively, where appropriate.
Data collect ed at screening that are used for inclusion/exclusion criteria, such as laboratory  
data, ECGs, and vital signs, will be considered source data, and may not be required to be 
reported, unless otherwise noted. Demographic data collected at screening will be reported.
9.4.1.1. Electrocardiogram Analyses
Changes from baseline for the ECG parameters QT interval, heart rate, QTcFinterval, PR 
interval, and QRS complex will be summarized by treatment and time.
The number (%) of participants with maximum post
-dose QTc Fvalues and maximum 
increases from baseline in the following categories will be tabulated by  treatment:
Safety QTc FAssessment
Degree of Prolongation Mild (msec) Moderate (msec) Severe (m sec)
Absolute value >450 -480 >480 -500 >500
Increase from baseline 30-60 >60

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 2020
PFIZER CONFIDENTIAL
Page 919.4.2. Secondary Endpoint :Pharmacokinetic Analyses
9.4.2.1. Derivation of Pharmacokinetic Parameters
Plasma PK parameters of PF-07304814 and PF- 00835231 to be derived (if data permit) from 
the concentration -time data using standard noncompartmental methods follo wing 24hor 
120h infusion are defined in Table 7and Table 8, respectivel y.Urine PF- 00835231 PK 
parameters following 24h infusion are defined in Table 9.
Actual PK sampling times will be used in the derivation of PK parameters. In the ca se that 
actual PK sampling times are not available, nominal PK sampling time will be used in the 
derivation of PK parameters.
Table 7. Plasma PF -07304814 and PF -00835231 PK Parameters Definitions for 
Part 1 : SAD (24-h Continuous Infusion)
Param eter Definition Method of Determ ination
C24 Concentration at 24h (end of infusion
in Part 1 )Observed directly from data
C24 (dn) Dose norm alized C 24 C24/Dose
Actual PK sampling times will be used in derivation of PK param eters.
Table 8.Plasma PF-07304814 and PF -00835231 PK Parameters for Pa rt 2: MAD
(120-h Continuous Infusion)
Param eter Definition Method of D eterm ination
C120 Concentration at 120h (end of 
infusion) Observed directly from data
Cmax Maximum observed concentration Observed directly from data
Css Steady state concentration Average concentration after achieving steady state
t1/2* Term inal half -life. Log e(2)/k el,
where k elis the terminal phase rate constant 
calculated by a linear regression of the loglinear 
concentration -time curve. Only those data points 
judged to describe the terminal loglinear decline 
will be used in the regression.
*If dat a permit.
Actual PK sampling times will be used in derivation of PK parameters.

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 2020
PFIZER CONFIDENTIAL
Page 93supporting clinical development. Unblinded results will be reviewed b y a desi gnated limited
number of sponsor colleagues within the study  team.
An independent IRC will assess whether it is safe to proceed to continued dosing after a 
small sentinel cohort of 2 participants within each dose- escalating cohort or if it is safe to 
dose-escalat e to the next dose level within Part 1.
9.6.Data Monitoring Committee or Other Independent Oversight Co mmittee
This study  will use a nindepend entIRC for Part 1.The IRC is independent of the study  team 
and includes Pfizer internal members. Emerging da ta will be reviewed b y the Investigator(s) 
(if available), the stud y team and the IRC. The IRC charter desc ribes the role of the IRC in 
more detail.
The IRCwill be responsible for ongoing monitoring of thesafet y of participant s in the study  
according to the charter. The recommendations made b y the IRC to alter the conduct of the 
study  will be forwarded to theappropriate Pfizer personnel for final decision. Pfizer will 
forward such decisions, which may  include summaries of aggregate analy ses of safety  data, 
to regulatory  authorities, as appropriate. 
The IRC will review the data collected for decision to proce ed to dosing of the rest of the 
cohort after the sentinel cohort in each dose -escalating cohort, as well as to proceed to the 
next dose level in Part 1 : SAD .The IRC may also be consulted at other times to review 
safet y data and in the event of unexpected safet y findings in study  C4611007 .

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 2020
PFIZER CONFIDENTIAL
Page 9410. S UPPORTING DOCU MENTATION AND OPERATIONAL CONSIDERATIONS
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.1. Regulatory and Ethical Considerations
This study  will be conducted in accordance with the protocol and with the following:
Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and CI OMS International Ethical Guidelines .
Applicable ICH GCP guidelines
.
Applicable laws and regulations , including applica ble privacy  laws .
The protocol, protocol ame ndments, I CD, SRSD(s) , and other relevant documents 
(eg,advertisements) must be 
reviewed and approved by  the sponsor and submitted to an 
IRB/EC by  the investigator and reviewed and approved by  the IRB/EC before the study  is 
initiated.
Any amendments to th e protocol will require IRB/EC approval before implementation of 
changes made to the study design, except for changes necessary  to eliminate an immediate 
hazard to study  participants.
The investigator will be res ponsible for the following:
Providing writte n summaries of the status of the study  to the IRB/EC annually  or 
more frequently  in accordance with the requirements, policies, and procedures 
established by  the IRB/EC .
Notify ing the IRB/EC of SAEs or other sign ificant safet y findings as required by 
IRB/EC procedures .
Providing oversight of the conduct of the stud y at the site and adherence to 
requirements of 21 CFR, ICH guidelines, the IRB/EC, European regulation 536/2014 
for clinical studies (if applicable), an d all other applicable local regulations.
10.1.1.1. Reporting of Safety Issues and Serious Brea ches of the Protocol or ICH GCP
In the event of an y prohibition or restriction imposed (ie, clinical hold) b y an applicable 
regulatory  authorit y in any area of the world, or if the investigator is aware of any  new
information that might influence the evaluation of the benefits and risks of the study  
intervention , Pfizer should be informed immediately . 
In addition, the investigator will inform Pfizer immediately  of any  urge nt safet y measures 
taken b y the investigat or to protect the study  participants against an y immediate hazard, and 
of an y serious breaches of this protocol or of ICH GCP that the investigator becomes aware 
of.

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 2020
PFIZER CONFIDENTIAL
Page 9510.1.2. Financial Disclosur e
Investigators and sub inves tigators will provide the sponsor with sufficient, accurate financial 
information as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory  authorities. Investigators 
are responsible for providing information on financial interests during the course of the stud y 
and for 1 year after completion of the study .
10.1.3. Informed Consent Process
The investigator or his/her representative will explain the nature of the study to the 
participant and answer all questions regard ing the study .The participant should be given 
sufficient time and opportunity  to ask questions and to decide whether or not to participate in 
the trial.
Participants must be informed that their participation is voluntary .Participants will be 
required to 
sign a statement of informed consent that meets the requirements of 21 CFR 50, 
local regulations, ICH guidelines, HIPAA requirements, where applicable, and the IRB/EC 
or study  center.
The investigator must ensure that each study  participant is fully  inform ed about the nature 
and objectives of the study, the sharing of data related to the study ,and possible risks 
associated with participation, including the risks associated with the processing of the 
participant ’s pers onal data. 
The participant must be inf ormed that his/her personal study -related data will be used by  the 
sponsor in accordance with local data protection law. The level of disclosure must also be 
explained to the participant.
The participant must be infor med that his/her medical records may  beexamined by  Clinical 
Quality  Assurance auditors or other authorized personnel appointed by  the sponsor, by  
appropriate IRB/EC members, and b y inspectors from regulatory authorities.
The investigator further must ensu re that each study  participant is fully informed about his or 
her right to access and correct his or her personal data and to withdraw consent for the 
processing of his or her personal data.
The medical record must include a statement that written informed consent was obtained 
before the partic ipant was enrolled in the study  and the date the written consent was obtained.
The authorized person obtaining the informed consent must also sign the IC D
.
Participants must be reconsented to the most current version of the IC D(s) during their 
participatio n in the study .
A cop y of the IC D(s) must be provided to the participant.

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 2020
PFIZER CONFIDENTIAL
Page 96A participant who is rescreened is not required to sign another IC Difthe rescreening occurs 
within 7days from the previous I CD signature dat e.
Unless prohibited by  local requireme nts or IRB/EC decision, t he ICDwill contain a separate 
section that addresses the use of samples for optional additional research. The optional 
additional research does not require the collection of an y further samples. The investigator or 
authorized designee will explain to each participant the objectives of the additional research.
Participants will be told that they  are free to refuse to participate and may  withdraw their 
consent at an y time and for an y reason duri ng the storage period. A separate signature will be 
required to document a participant's agreement to allow specimens to be used for additional
research. Participants who decline to participate in this optional additional research will not 
provide this sep arate signature .
10.1.4. Data Protection
All parties will comply  with all applicable laws, including laws regarding the implementation 
of organizational and technical measures to ensure protection of participant data.
Participants’ personal data will be stored at the 
study  site in encry pted electronic and/or paper 
form and will be password protected or secured in a locked room to ensure that only  
authorized study  staff have access. The stud y site will implement appropriate technical and 
organizational measures to e nsure that the personal data can be recovered in the event of 
disaster. In the event of a potential personal data breach, the study site will be responsible for 
determining whether a personal data breach has in fact occurred and, if so, providing breach 
notifi cations as required by  law.
To protect the rights and freedoms of participants with regard to the processing of personal 
data, participants will be assigned a single, participant -specific numerical code. Any 
participant records or data sets that are tr ansferred to the sponsor will contain the numerical 
code; participant names will not be transferred. All other identifiable data transferred to the 
sponsor will be identified by  this single, 
participant- specific code. The study  site will 
maintain a confide ntial list of participant s who participated in the study, linking each 
participant ’s numerical code to his or her actual identity and medical record identification .In 
case of data transfer, the sponsor will protect the confidentiality  of participants’ per sonal data 
consistent with the c linical study agreement and applicable privacy  laws.
10.1.5. Dissemination of Clinical Study Data
Pfizer fulfills its commitment to publicly  disclose clinical study  results through posting the 
results of studies on www.clinicaltrials.gov (ClinicalTrials.gov), the EudraCT, and/or 
www.pfizer.com, and other public registries in accordance with applicable local 
laws/regulations. In addition, Pfizer reports study  results outside of the requirements of local 
laws/regulatio ns pursuant to it s SOPs.
In all cases, stud y results are reported b y Pfizer in an objective, accurate, balanced, and 
complete manner and are reported regardless of the outcome of the stud y or the country in 
which the study  was conducted.

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 2020
PFIZER CONFIDENTIAL
Page 97www.clinicaltrials .gov
Pfizer posts clinical trial results on www.clinicaltrials.gov for Pfizer- sponsored interventional 
studies (conducted in patients) that evaluate the safety  and/or efficacy  of a product, 
regardless of the geographical location in which the study  is conducted. These r esults are 
submitted for posting in accordance with the format and timelines set forth by  US law.
EudraCT
Pfizer posts clinical trial r esults on EudraCT for Pfizer -sponsored interventional studies in 
accordance with the format and timelines set forth by  EU re quirements.
www.pfizer.com
Pfizer posts public disclosure s ynopses (CSR synopses in which an y data that could be used 
to identify  individual participants have been removed) on www.pfizer.com for 
Pfizer -sponsored interventional s tudies at the same time the corresponding study  results are
posted to www.clinicaltrials.gov .
Documents within marketing authorization packages/submissions
Pfizer complies with the European Union Policy  0070, the proactive publication of clinical 
data to t he EMA website. Clinical data, under Phase 1 of this policy , includes clinical 
overviews, clinical summaries, CSRs, and appendices containing the protocol and protocol 
amendments, sample CRFs, and statistical methods. Clinical data, under Phase 2 of this 
policy , includes the publishi ng of individual participant data. Policy  0070 applies to new 
marketing authorization applications submitted via the centralized procedure since 
01January 2015 and applications for line extensions and for new indications submit ted via 
the centralized proc edure since 01 July  2015.
Data Sharing
Pfizer provides researchers secure access to patient- level data or full CSRs for the purposes 
of “bona -fide scientific research” that contribute sto the scientific understanding of the 
disease, target, or compound cla ss.Pfizer will make available data from these trials 
24months after study  completion. Patient- level data will be anon ymized in accordance with 
applicable privacy  laws and regulations. CSRs will have personally  identifiable information 
redacted.
Data requ ests are considered from qualified researchers with the appropriate competencies to 
perform the proposed analy ses.Research teams must include a biostatistician. Data will not 
be provi ded to applicants with significant conflicts of interest, including indi viduals 
requesting access for commercial/competitive or legal purposes.

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 2020
PFIZER CONFIDENTIAL
Page 9810.1.6. Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically  (eg, labora tory data). The investigator is 
responsible for verify ing that data entries are accurate and correct by  physically  or 
electronically  signing the CRF.
The investigator must maintain acc urate documentation (source data) that supports the 
information entered in the CRF.
The investigator must ensure that the CRFs are securel y stored at the study site in encrypted 
electronic form and are password protected to prevent access b y unauthorized t hird parties.
The investigator must permit study -related monitoring, aud its, IRB/EC review, and 
regulatory  agency  inspections and provide direct access to source data documents. This 
verification may  also occur after study  completion. It is important that the investigator(s) and 
their relevant personnel are available during th e monitoring visits and possible audits or 
inspections and that sufficient time is devoted to the process.
Monitoring details describing strategy  (eg, risk- based initiatives in operati ons and quality  
such as risk management and mitigation strategies and analytical risk-based monitoring), 
methods, responsibilities ,and requirements, including handling of noncompliance issues and 
monitoring techniques (central, remote, or on -site monitori ng),are provided in the 
monitoring plan.
The sponsor or designee is res ponsible for the data management of this study ,including 
quality  checking of the data.
Study  monitors will perform ongoing source data verification to confirm that data entered 
into t he CRF by  authorized site personnel are accurate, complete, and verifiab le from source 
documents; that the safety and rights of participants are being protected; and that the study  is 
being conducted in accordance with the currently
 approved protocol and a ny other study  
agreements, I CH GCP, and all applicable regulatory  requir ements.
Records and documents, including signed IC Ds, pertaining to the conduct of this study  must 
be retained b y the investigator for 15years after study  completion unless local regulations or 
institutional policies require a longer retention period. No records may  be destroy ed during 
the retention period without the written approval of the sponsor. No records may  be 
transferred to anothe r location or party without written notification to the sponsor. The 
investigator must ensure that the records continue to be stored securel y for aslong as they  are 
maintained.
When participant data are to be deleted, the investigator will ensure that all copies of such 
data are promptly  and irrevocabl y deleted from all systems.

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 2020
PFIZER CONFIDENTIAL
Page 99The investigator(s) will notify thesponsor or its agents immediately  of any  regulatory  
inspection notification in relation to the study .Furthermore, the investigator will coopera te 
with the sponsor or its agents to prepare the investigator site for the inspection and will allow 
the sponsor or its agent, whenever feasible, to be present during the inspection. The 
investigator site and investigator will promptly  resolve any  discrepa ncies that are identified 
between the stud y data and the participant's medical records. The investigator will promptly  
provide copies of the inspection findings to the sponsor or its agent. Before response 
submission to the regulatory  authorities, the inve stigator will provide the sponsor or its 
agents with an opportunity to review and comment on responses to an y such find ings.
10.1.7. Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrit y of the data collected. Source document s are filed at the investigator site.
Data reported on the CRF or entered in the eCRF that ar e from source documents must be 
consistent with the source documents or the discrepancies must be explained .The 
investigator may  need to request previous medical records or transfer records, depending on 
the study .Also, current medical records must be available.
Definition of what constitutes source data can be found in the study  monitoring plan .
Description of the use of computerized sy stem is documented in the Data Management Plan .
10.1.8. Study and Site Start and Closure
The study  start date is the date on which the clinical study  will be open for recruitment of 
participants.
The first act of recruitment is the date of the first participant’s first visit and will be the study  
start date.
The sponsor designee reserves the right to close the study  site or termina te the study  at any  
time for an y reason at the sole discretion of th e sponsor. Study  sites will be closed upon study  
completion. A study  site is considered closed when all required documents and study  
supplies have been collected and a stud y-site closure v isit has been performed.
The investigator may  initiate study -site cl osure at any  time upon notification to the sponsor 
or designee/CRO if requested to do so by  the responsible I RB/EC or if such termination is 
required to protect the health of study  partici pants .
Reasons for the earl y closure of a stud y site b y the sponsor may include but are not limited 
to:
Failure of the investigator to comply  with the protocol, the requirements of the 
IRB/EC or local health authorities, the sponsor's procedures, or GCP gu idelines.

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 2020
PFIZER CONFIDENTIAL
Page 100Inadequate recruitment of participants by  the investigator.
Discontinuation of further study  intervention development .
If the stud y is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators, the ECs/IRBs, the reg ulatory  authorities, and any  CRO (s) used in the study  of 
the reason 
for termination or suspension, as specified by  the applicable regulatory  
requirements. The investigator shall promptly  inform the participant and should assure 
appropriate participant therapy and/or follow -up.
Study  termination is also provided for in the clinical study  agreement. If there is an y conflict 
between the contract and this protocol, the contract will control as to termination rights.
10.1.9. Publication Policy
The results of this study  may be published or presented at scientific meetings b y the 
investigator after publication of the overall study  results or 1year after the end of the stud y 
(or study  termination), whichever comes first. 
The investigator agrees to refer to the primary  publication in any  subsequent publications 
such as secondary  manusc ripts and submit s all manuscripts or abstracts to the sponsor 
30days before submission. This allows the sponsor to protect proprietary  information and to 
provide comments and the investigator will, on request, remove an y previously  undisclosed 
confidentia l information before disclosure, except for any  study -or Pfizer 
intervention -related information necessary  forthe appropriate scientific presentation or 
understanding of the study  results.
For all publications relating to the stud y, the investigator will compl y with recognized ethical 
standards concerning publications and authorship, including those established by  the 
International Committee of Medical Journal Editors.
The sponsor will comply with the requirements for publication of the over all study  resu lts 
covering all i nvestigator sites. In accordance with standard editorial and ethical practice, the 
sponsor will support publication of multicenter studies only  in their entirety and not as 
individual site data. In this case, a coordinating investigator w ill be designated b y mutual 
agreement.
Authorship of publications for the overall study  results will be determined by  mutual 
agreement and in line with I nternational Committee of Medical Journal Editors authorship 
requirements. 
If publication is addressed in the clinical study  agreement, the publication policy  set out in 
this section will not apply.

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 2020
PFIZER CONFIDENTIAL
Page 10110.1.10. Sponsor’s Qualified Medical Personnel
The contact information for the sponsor's appropriately  qualified medical personnel for the 
study  is documented in the study contact list located in the SToD sy stem . 
To facilitate access to appropriatel y qualified medical personnel on stud y
-related medical 
questions or problems, participant s are provided with a contact card at the time of informed 
consent . The contact card contains, at a minimum, protocol and study  intervention identifiers, 
participant numbers, contact information for the investigator site, and contact details for a 
contact center in the event t
hat the investigator site staff cannot be reach ed to provide advice 
on a medical question or problem originating from another healthcare professional not 
involved in the participant ’s participation in the study .The contact number can also be used 
by inves tigator staff if they  are seeking advice on med ical questions or problems; however, it 
should be used only  in the event that the established communication pathway s between the 
investigator site and the study  team are not available. It is therefore intended to augment, but 
not replace, the established c ommunication pathway s between the investigator site and the 
study  team for advice on medical questions or problems that may  arise during the study .
The 
contact number is not intended for use b y the participant directl y, and if a participant calls 
that number, he or she will be directed back to the investigator site.

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 2020
PFIZER CONFIDENTIAL
Page 10210.2. Appendix 2: Clinical Laboratory Tests
The following safet y laboratory  tests will be performed at times defined in the SoA section of 
this protocol. Additional laboratory  results may  be reported on these samples as a result of 
the method of anal ysis or the ty pe of anal yzer used by  the clinical laboratory ,or as derived 
from calculated values. These additional tests would not r equire additional collection of 
blood. Unschedul ed clinical laboratory
 measurements may  be obtained at any  time during the 
study  to assess an y perceived safet y issues.
Table 10.Protocol -Required Safety Laboratory Assessments
Hem atology Chemistry Urinalysis Other
Hem oglobin
Hem atocrit
RBC count
MCV
MCH
MCHC
Platelet count
WBC count
Total neutrophils 
(Abs)
Eosinophils (Abs)
Monocytes (Abs)
Basophils (Abs)
Lymphocytes (Abs)BUN 
serum creatinine (and 
eGFR using 
Cockcroft -Gault)
Gluc ose
Calcium
Sodium
Potassium
Chloride
Total 
CO 2(bicarbonate)
AST, ALT
Phosphorus
Total bilirubin
Alkaline phosphatase
Uric acid
Albumin
Total protein
Lipid panel (Part 2 
only)pH
Glucose (qual)
Protein (qual)
Blood (qual)
Ketones
Nitrites
Leukocyte esterase
Urobilinogen
Urine bilirubin
MicroscopyaAt screen ingonly:
FSHb
Pregnancy test ( -hCG )c
At timepoints in SoA:
Coagulation 
D-dimer
PT/INR
aPTT
Fibrinogen
a.Only if urine dipstick is positive for blood, protein, nitrites ,or leukocyte esterase.
b.For confirmation of post meno pausal status only.
c.Local urine testing will be standard for the protocol unless serum testing is required by local regulation 
or IRB/EC. Serum or urine -hCG for female participant s of childbearing pote ntial.
Investigators must document their review of each laboratory  safet y report.

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 2020
PFIZER CONFIDENTIAL
Page 105should be considered serious.
Hospitalization for elective treatment of a preexisting condition that did not worsen from 
baseline is not considered an AE.
d.Results in persistent disability/inc apacity
The term disability  means a substantial disruption of a person’s ability  to conduct 
normal life functions.
This definition is not intended to include experiences of relativel y minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, 
influenza, and accidental trauma (eg, sprain ed ankle) which may  interfere with or 
prevent every day life functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
f.Other situations:
Medical or scientific judgment should be exercised in deciding whether SAE 
report ing is appropriate in other situations such as important medical events that 
may not be immediatel y life-threatening or result in death or hospitalization but 
may jeopardize the partic ipant or may  require medical or surgical intervention to 
prevent one of the other outcomes listed in the above definition. These events 
should usually  be considered serious.
Examples of such events include invasive or malignant cancers, intensive treatment
in an emergency  room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in hospitalization, or development of drug 
dependency  or drug abuse.
Suspected transmission via a Pfizer product of an infectious agent, pathogenic or 
non-pathogenic, is considered serious. The event may  be suspected from clinical 
symptoms or laboratory  findings indicating an infection in a patient exposed to a 
Pfizer product. The terms “suspected transmission” and “transmission” are 
consid
ered s ynon ymous. These cases are considered unexpected and handled as 
serious ex pedited cases by pharmacovigilance personnel. Such cases are also 
considered for reporting as product defects, if appropriate.

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 2020
PFIZER CONFIDENTIAL
Page 11010.4. Appendix 4: Contraceptive Guidance 
10.4.1. Male Participant Reproductive Inclusion Criteria
Male participants are eligible to participate if they  agree to the following requirements during 
the intervention period and for at least 3 day s after the last dose of stud y intervention, which
corresponds to the time needed to eliminate reproductive safet yrisk of the study  
intervention(s):
Refrain from donating sperm.
PLUS either :
Be abstinent from heterosexual intercourse with a female of childbearing potential as 
their preferred and usual li festy le (abstinent on a long -term and persistent basis) and 
agree to remain abstinent .
OR
Must agree to use a male condom when engaging in any  activity  that allows for 
passage of ejaculate to another person .
In addition to male condom use, a highl y effect ive method of contraception may  be 
considered in WOCBP partners of male participants (refer to the 
list of highly  effective 
methods below in Section 10.4.4 ).
10.4.2. Female Participant Reproductive Inclusion Criteria
A female participant is eligible to participate i f she is not pregnant or breastfeeding, and at 
least 1 of the following conditions applies:
Is not a WOCBP (see definitions below in Section 10.4.3).
OR
Is a WOCBP and using a contraceptive met
hod that is highly  effective (with a failure 
rate of <1% per year), as described below, during the intervention period and for at 
least 28 day safter the last dose of study  intervention, which corresponds to the time 
needed to eliminate an y reproductive sa fety risk of the study intervention(s). If a 
highl y effective method that is user dependent is chosen, a second effective method of 
contraceptio n, as described below, must also be used. The investigator should 
evaluate the effectiveness of the contraceptiv e method in relationship to the first dose 
of study  intervention.
The investigator is responsible for review of medical history , menstrual history , and 
recent sexual activity  to decrease the risk for inclusion of a woman with an earl y 
undetected pregnancy .

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 2020
PFIZER CONFIDENTIAL
Page 11110.4.3. Woman of Childbearing Potential
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanentl y sterile ( see below).
If fertility  is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cy cle cannot 
be confirmed before the first dose of study  intervention, additional evaluation should be 
considered.
Women in the following categories are notconsidered WOCBP:
Premenopausal female with 1 of the following:
Documented h ysterectomy .
Documented bilateral salpi ngectomy .
Documented bilateral oophorectom y.
For individuals with permanent infertility  due to an alternate medical cause other than the 
above, (eg, mullerian agenesis, androgen insensitivity ), investigator discretion should be 
applied to determining study entry .
Note: Documentation for any of the above categories can come from the site personnel’s 
review of the participant’s medical records, medical examination, or medical history  
interview. The method of documentation should be recorded in the participant ’s medical 
record for the stud y.
Postmenopausal female :
A postmenopausal state is defined as no menses for 12 months without an 
alternative medical cause. In addition, a
High FSH level in the postmenopausal range must be used to confirm a 
postmenopausal st ate in women under 60 years of age and not using hormonal 
contraception or HRT. 
Female on HRT and whose menopausal status is in doubt will be required to 
use one of the nonestrogen hormonal highly effective contraception methods 
if they  wish to continue t heir HRT during the study. Otherwise, they  must 
discontinue HRT to allow confirmation of postmenopausal status before study  
enrolment .

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 2020
PFIZER CONFIDENTIAL
Page 11210.4.4. Contracepti onMethods
Contraceptive use b y men or women should be consistent with local availability /regulations 
regardin g the use of contraceptive methods for those participating in clinical trials. Female 
participants utilizing hormonal contracept ion, including those with hormonal intrauterine 
devices placed, cannot participate in the study  since hormonal contraception is not permitted. 
Highly Effective Methods That Have Low User Dependency
1.Non hormonal intrauterine device
2.Bilateral tubal occlusio n.
3.Vasectomized partner :
Vasectomized partner is a highl y effective contraceptive method provided that the 
partner is the sole s exual partner of the woman of childbearing potential and the 
absence of sperm has been confirmed. If not, an additional highly  effective 
method of contraception should be used. The spermatogenesis cy cle is 
approximately  90 day s.
 Highly Effective Methods Th at Have Low User Dependency
4.Sexual abstinence :
Sexual abstinence is considered a highl y effective method only if defined as 
refraining from heterosexual intercourse during the entire period of risk associated 
with the study  intervention. The reliability  ofsexual abstinence needs to be 
evaluated in relation to the duration of the stud y and the preferred and usual
lifesty le of the participant.

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 2020
PFIZER CONFIDENTIAL
Page 11410.6. Appen dix 6: Liver Safety: Suggested Actions and Follow- up Assessments
Potential Cases of Drug- Induced Liver Injury
Humans exposed to a drug who show no sign of liver injury  (as determined by  elevations in 
transaminases) are termed “tolerators ,” while those who show transient liver injury , but adapt 
are termed “adaptors.” In some participant s, transaminase elevations are a harbinger of a 
more serious potential outcome. These participant s fail to adapt and therefore are 
"susceptible" to progressive and serious liv er injury , commonl y referred to as DILI.
Participant s who experience a transaminase elevation above 3 ×ULN should be monitored 
more frequently  to determine if they  are an “adaptor” or are “susceptible.”
In the majority  of DILI cases, elevations in AST and/or ALT precede TBili elevations 
(>2×ULN) b y several day s or weeks. The increase in TBili ty pically  occurs while AST/ALT 
is/are still elevated above 3 ×ULN (ie, AST/ALT and TBili values will be elevated within 
the same lab oratory sample). In rare instances, by the time TBili elevations are detected, 
AST/AL T values might have decreased. This occurrence is still regarded as a potential DILI.
Therefore, abnormal elevations in either AST OR AL T in addition to TBili that meet the 
criteria outlined below are c onsidered potential DILI (assessed per Hy ’s law criteria) cases
and should alway s be considered importa nt medical events, even before all other possible 
causes of liver injury  have been excluded.
The threshold of laboratory abnormalities for a potential DI LI case depends on the 
participant ’s individual baseline values and underly ing conditions. Participant swho present 
with the following laboratory  abnormalities should be evaluated further as potential DILI 
(Hy’s law) cases to definitively  determine the eti ology  of the abnormal laboratory  values:
Participant s with AST/ALT and TBili baseline values within the normal range who 
subsequently  present with AST OR AL T values >3 ×ULN AND a TBili value 
>2× ULN with no evidence of hemol ysis and an alkaline phosphata se value 
<2×ULN or not available.
For participant s with baseline AST OR ALT ORTBili values above the ULN, the 
following threshold values are used in the definition mentioned above, as needed, 
depending on which values are above the ULN at baseline:
Preexisting AST or ALT baseline values above the normal range: AST or ALT 
values >2 times the baseline values AND >3 × ULN; or >8 ×ULN (whichever is 
smaller).
Preexisting values of TBili above the normal range: TBili level increased from 
baseline value b y an amount of at least 1 × ULN orif the value reaches 
>3×ULN (whichever is smaller).

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 2020
PFIZER CONFIDENTIAL
Page 115Rises in AST/AL T and TBili separated by  more than a few weeks should be assessed 
individually  based on clinical judgment; any  case where uncertainty  remains as to whether i t 
represents a potential Hy’s law case should be reviewed with the sponsor. 
The participant should return to the investigator site and be evaluated as soon as possible, 
preferabl y within 48 hours from awareness of the abnormal results. This evaluation sho uld 
include laboratory  tests, detailed history , and physical assessment.
In addition to repeating measu rements of AST and AL T and TBili for suspected cases of 
Hy’s law, additional laboratory  tests should include albumin, CK, direct and indirect 
bilirubin, GGT, PT/I NR, total bile acids, and alkaline phosphatase. Consideration should also 
be given to drawing a separate tube of clotted blood and an anticoagulated tube of blood for 
further testing, as needed, for further contemporaneous anal yses at the time of the recognized 
initial abnormalities to determine etiology .A detailed history , including relevant information, 
such as review of ethanol, acetaminophen /paracetamol (either b y itself or as a coformulated 
product in prescription or over -the-counter medicati
ons), recreational drug, supplement 
(herbal) use and consump tion, family  history , sexual history , travel history, history  of contact 
with a jaundiced person, surgery , blood transfusion, history  of liver or allergic disease, and 
potential occupational expos ure to chemicals, should be collected. Further testing for a cute 
hepatitis A, B, C, D, and E infection and liver imaging (eg, biliary  tract) and collection of 
serum sample sfor acetaminophen /paracetamol drug and/or protein adduct levels may  be 
warranted. 
All cases demonstrated on repeat testing as meeting the labo ratory  criteria of AST/AL T and 
TBili elevation defined above should be considered potential DILI (Hy ’s law) cases if no 
other reason for the LFT abnormalities has yet been found. Such potential DI
LI (Hy’s law) 
cases are to be reported as SAEs, irrespective of availability of all the results of the 
investigations performed to determine etiology of the LFT abnormalities.
A potential DILI (Hy ’s law) case becomes a confirmed case onl y after all result s of 
reasonable investigations have been received and have e xcluded an alternative etiology .

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 2020
PFIZER CONFIDENTIAL
Page 11810.8. Appe ndix 8: Prohibited Medications 
Use of an y medication or substance that are strong inhibitors ( Table 11) or inducers 
(Table 12) of CYP3A4 is not permitted. Examples of some common medications that are 
strong inhibitors or inducers CYP3A4 are provided in the tables below. These lists are not 
comprehensive.
Table 11. Common Medications That Inhibit CYP450 3A4a
Category Examples
Antiretrovirals Indinavir, nelfinavir, ritonavir, saquinavir, delavirdine, amprenavir, 
fosamprenavir, atazanavir, cobicistat, lopinavir, danopravir, boceprivir
Antifungal: Itraconazole, ketoconazole, voriconazole, posaconazole
Anti-infectives Macrolides: telithromycin, clarithrom ycin
Antidepressants Nefazodone
Antineoplastic Idelalisib
a.Not a comprehensive list.
Table 12.Common Medications That Induce CYP450 3A4a
Category Examples
Anti-infectives Rifampin
Anti-epileptic Phenytoin, carbamazepine
Psychoactive drugs St. John's wort
a.Not a comprehensive list.
For concomitant medications metabolized primarily  via CYP3A, recommendations for dose 
modifications and/or precautions should be implemented according to their labeled drug 
interaction potent ial with CYP3A inhibitors. 
For concomitant use of drugs that are substrates of P -gp, BCRP, OATP1B1/1B3, OCT1, and 
MATE1/2K transporters, recommendations for dose modifications and/or precautions should 
be implemented according to their labeled drug interaction potential with transporters
inhibitors.

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 2020
PFIZER CONFIDENTIAL
Page 11910.9. Appendix 9: Abbreviations
The following is a list of abbreviations that may  be used in the protocol.
Abbreviation Term
Abs absolute
ACE angiotensin converting enzy me
ACE2 angiotensin converting enzy me 2
AE adverse event
ALT alanine aminotransferase
aPTT activated partial thromboplastin time 
ARDS Acute Respiratory  Distress Sy ndrome
AST aspartate aminotransferase
AUC area under the curve
AUC 24 area under the curve from time 0 to 24 hours
AUC inf area u nder the plasma concentration -time profile from time 0 
extrapolated to infinite time
AUC last area under the plasma concentration -time profile from time 0 to the time 
of the last quantifiable concentration
AUMC inf area under the first moment curve from ti me 0 extrapolate d to infinite 
time
AV atrioventricular
-hCG beta-human chorionic gonadotropin
BCRP breast cancer resistance protein
BID twice dail y
BLQ below limit of quantification
BMI body  mass index
BP blood pressure
BUN blood urea nitrogen
C24 concentration at 24 hours
C120 concentration at 120 hours
CC 50 50% cy totoxic concentration
Ceff efficacious concentration
CFR Code of Federal Regulations
CIOMS Council for International Organizations of Medical Sciences
CK creatine kinase
CL clear ance
Clast last quantifiable concentration
CL p plasma clearance
Cmin minimum observed concentration
Cmax maximum observed concentration
Cmax, free maximum free observed concentration
CO 2 carbon dioxide (bicarbonate)
CONSORT Consolidated Standards of Reporting Trials

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 2020
PFIZER CONFIDENTIAL
Page 120Abbreviation Term
CoV Coronavirus
COVID -19 Coronavirus Disease 2019
CPE cytopathic effect
CL cr creatinine clearance
COVID Corona virus infectious disease
CRF case report form
CRO contract research organization
CRU clinical research unit
CSR Clinic al Study  Report
Css concentration at stead y state
CT Clinical trial
CT Scan computerized tomography  scan
CTG Cell Titer -Glo (luminescent cell viability  assay )
CV cardiovascular
CYP Cytochrome P450
DDI drug-drug interaction
DILI drug-induced liver i njury
dn Dose normalized
DNA deox yribonucleic acid
DOF duration of IV infusion 
DVT deep vein thrombosis
EC ethics committee
EC 50 50% effective concentration
EC 90 90% effective concentration
ECG electrocardiogram
ECMO Extracorporeal membrane ox ygenation
eCRF electronic case report form
EDP exposure during pregnancy
EGFP enhanced green fluorescent protein
eGFR estimated glomerular filtration rate
EI efflux inhibitor
EMA European Medicines Agency
EOT end of treatment
EU European Union
EUA Emergency  Use Authorization
EudraCT European Clinical Trials Database
FDA Food and drug administration
FIP First in Patient
fm fraction of metabolism
FOB functional observation battery
FSH follicle -stimulating hormone
FU follow -up

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 2020
PFIZER CONFIDENTIAL
Page 121Abbreviation Term
GCP Good Clinical P ractice
GGT gamma -glutamy l transferase
GLP Good Laboratory  Practice
h hour(s)
HAE human airway  epithelium
HCV hepatitis C
hERG human Ether -a-go-go Related Gene
HIPAA Health Insurance Portability  and Accountability  Act
HIV human immunodeficiency vir us
HR heart rate
HRT hormone replacement therap y
hsCRP high sensitivity  C-Reactive Protein
Huh7 human hepatocellular carcinoma cells-7
HV healthy  volunteer
IB Investigator’s Brochure
ICD informed consent document
ICH International Council for Harmo nization
ID identification
IFN-γ Interferon gamma
IL interleukin
IMP investigational medicinal product
IND Investigational New Drug
INR international nor malized ratio
IP investigational product 
IP-10 interferon -inducible protein 10
IPAL Investig ational Product Accountability  Log
IRB Institutional Review Board
IRC internal review committee
IRT Interactive Response Technology
IV intravenous
K3EDTA dipotassium ethy lenediaminetetraacetic acid
Kel terminal phase rate constant
LBBB left bundle b ranch block
LDH Lactate dehy drogenase
LFT liver function test
Loge natural logarithm
MA mouse -adapted
MAD multiple ascending dose
MATE multidrug and toxi c compound extrusion transporter
MCH mean corpuscular hemoglobin
MCHC mean corpuscular hemoglob in concentration
MCV mean corpuscular volume

PF-07304814
Protocol C4611001Final Protocol Amendment 4, 15 December 2020
PFIZER CONFIDENTIAL
Page 122Abbreviation Term
MRC-5 Medical Research Council cell strain 5 – human lung fibroblast
msec millisecond
N/A not a pplicable
NIH National Institute of Health
NIMP Non-investigational medicinal product
NOAEL no-observed-adverse-effect level
NYU New York University
OCT organic cation transporte r
OATP organic anion transporting polypeptides
PD pharmacodynamic(s)
PE Physical exam
P-gp P-glycoprotein
PK pharmacokinetic(s)
proBNP Pro-B-Type Natriuretic Peptide
PT prothrombin time
PVC premature ventricular contraction/complex
QRS Q wave to the end of the S wave corresponding ventricle depolarization
QTc corrected QT interval
QTcF corrected QT using Fridericia’s formula
qual qualitative
RBC red blood cell
Rega Rega Institute
RNA ribonucleic acid
RT-PCR Reverse transcription polymerase chain reaction
SAD single ascending doses
SAE serious adverse event
SAP Statistical Analysis Plan
SARS severe acute respiratory syndrome
SARS-CoV-1 Severe Acute Respiratory Syndrome-Coronavirus-1
SARS-CoV-2 Severe Acute Respiratory Syndrome-Coronavirus-2
SBP Systolic blood pressure
s.c subcutaneous
SoA schedule of activities
SoC standard of care
SOP standard operating procedure
SpO 2 oxygen saturation
SRI Southern Research Institute
SRSD single reference safety document
SToD study team on demand
SUSAR Suspected Unexpected Serious Adverse Reaction
t½ terminal half-lifeCCI
PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 2020
PFIZER CONFIDENTIAL
Page 123Abbreviation Term
TBD to be determined
TBili total bilirubin
TEAE treatment -emergent adverse event
TI Therapeutic Index
TNF -α Tumor Necrosis Factor -α
ULN upper limit of normal
US United States
Vss Steady -state volume of distribution 
WBC white blood c ell
WOCBP woman of childbearing potential

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 2020
PFIZER CONFIDENTIAL
Page 12411.REFERENCES
1. WHO Situation Report 51. 11 March 2020 Av ailable from : 
https://www.who.int/emergencies/diseases/novel- coronavirus- 2019/situation -reports. 
Accessed : 29 March 2020.
2. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus 
disease 2019 (COVID -19) outbreak in China: summary ofa report of 72 314 cases from
the Chinese Center for Disease Control and Prevention. JAMA 2020;323(13):1239 -42.
3. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, 
and outcomes among 5700 patients hospitalized with COV ID-19 in the New York City  
area. JAMA 2020;323(20):2052-9.
4. Dochert y AB, Harrison EM, Green CA, et al. Features of 20  133 UK patients in hospital 
with covid-19 using the I SARI C WHO Clinical Characterisation Protocol: prospective 
observational cohort study. BMJ 2020;369:m1985.
5. Wang D, Hu B, Hu C, et al. 
Clinical characteristics of 138 hospitalized patients with 
2019 novel coronavirus -infected pneumonia in Wuhan, C hina. JAMA 
2020;323(11):1061 -9.
6. Cummings MJ, Baldwin MR, Abrams D, et al. Epidemiology , clinical course, and 
outcomes of criticall y ill adults with COVI
D-19 in New York Cit y: a prospective cohort 
study . Lancet 2020;395(10239):1763-70.
7. Chen T, Wu D, Chen H, et al. Cli nical characteristics of 113 deceased patients with 
coronavirus disease 2019: retrospe ctive study. BMJ 2020;368:m1091.
8. Mao L , Jin H, Wang M, et al. Neurologic Manifestations of Hospitalized Patients With 
Coronavirus Disease 2019 in Wuhan, China. JAMA Neuro l. 2020;77(6): 683-90.
9. Mehta P, McAuley  DF, Brown M, et al. COVID -19: consider cy tokine storm 
syndromes and immunosuppression. Lancet 2020;395(10229):1033
-4.
10. Beigel JH, Tomashek KM, Dodd L E et al. Remdesivir for the treatment of 
Covid -
19final re port. N Engl J Med. 2020:1 -14.
11. US FDA. Remdesivir letter of EUA. 
Available from: 
https://www.fda. gov/media/137564/download. Accessed : 14June 2020 .
12. Summary  on compassionate use ( Remdesivir ). Available from : 
https://www.ema.europa.eu/en/documents/other/su mmary -compassionate -use-
Remdesivir -gilead_en.pdf .Accessed : 17June 2020.

PF-07304814
Protocol C4611001
Final Protocol Amendment 4 , 15December 2020
PFIZER CONFIDENTIAL
Page 12625. Shen L , Peterson S, Sedaghat AR, et al. Dose -response curve slope sets class -specific 
limits on inhibitory  potentia l of anti -HIV drugs. Nat Med .2008;14(7):762 -6.
